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Abstract: Nanotechnology applications have emerged enormously in recent 
times. Of particular interest is that area that overlaps the areas of 
nanotechnology, biology and medicine: nanomedicine. One advantage of 
nanomedicines is it that it can be used as an enabling technology by 
pharmaceutical researchers and industry to overcome issues associated with 
the low bioavailability of hydrophobic drugs. In the first part of the current study, 
nanosuspensions of two of hydrophobic steroid drugs: hydrocortisone and 
prednisolone were produced. Nanosuspensions were prepared using a bottom-
up approach: the anti-solvent precipitation method using microfluidic reactors. 
Surface modification was carried out on these nanosuspensions using cationic 
surfactants to obtain nanoparticles with different levels of surface positive 
charge as indicated by -potential values. Dynamic light scattering (DLS) and 
transmission electron microscope (TEM) techniques were used to characterize 
the prepared nanoparticles. Powder X-ray diffraction (PXRD) and differential 
scanning calorimetry (DSC) were also used to characterize hydrocortisone 
nanoparticles. In the second part, cellular uptake of both coated and uncoated 
nanoparticles by HaCaT keratinocytes cell line was examined and indicated by 
quantifying the anti- inflammatory effect of nanoparticles on the LPS-induced 
inflammation. Also, TEM was employed to evaluate the cellular uptake of 
hydrocortisone nanoparticles. Results showed higher ant-inflammatory effect of 
coated nanoparticles over uncoated nanoparticles. Furthermore, the anti-
inflammatory effect of coated nanoparticles was correlated to the degree of 
positive surface charge.         
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1.1. Nanomedicine 
Nanotechnology is the science of creating and dealing with devices and 
materials on nano-sized scale. This terminology is derived from the Greek word 
"nano" which means dwarf. Scientific groups have debated the size range of 
nanoparticles, as some may limit it to 1 – 100 nm, as defined by the National 
Nanotechnology Initiative (NNI) (Jain, 2008).  However, it is generally accepted 
in drug delivery, that particles sizes up to 1 micron are considered to be termed 
nanoparticles under the umbrella term of nanotechnology (Garnett and 
Kallinteri, 2006, Remington: The science and practice of pharmacy, 2005). 
Currently, nanotechnology has a range of diverse applications in both medical 
and chemical research areas, and real advances in exploring different fields of 
nanotechnology are now developing worldwide. It is anticipated (Bawa, 2009) 
that in the coming 15 years, a huge increase in the workforce with appropriate 
nanotechnology skills will occur from the current figure of 20.000 researchers to 
beyond 2 million.  
The area of nanotechnology that interacts with biological processes and 
functions is known as bionanotechnology.  Nanomedicine – as was recently 
referred to by the National institutes of Health (Bethesda, MD, USA) – is the 
application of bionanotechnology in the prevention, diagnosis and treatment of 
diseases, research in this area has greatly expanded in the last decade  
(Moghimi et al., 2005).  
Nanotechnology within the context of drug development is concerned with the 
design and production of active pharmaceutical materials at the submicron 
scale. These nanosized therapeutic materials are known as 
nanopharmaceuticals or nanomedicines. 
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Nanoparticles are defined as ranging in size from 10 - 1000 nm (Mohanraj and 
Chen, 2006) and are currently employed in the preparation of numerous 
pharmaceutical dosage forms such as nanoemulsions (Calvo et al., 1996) and 
nanosuspensions (Patravale et al., 2004, Rabinow, 2004). Nanosuspensions of 
active pharmaceutical ingredients (API) are defined as stabilized colloidal 
particulate dispersions of sub-micron-scaled particles of drugs (Rabinow, 2004). 
 
1.1.1. Advantages of nanomedicines  
From the pharmaceutical view, the main advantage of preparing APIs as nano-
sized particles (e.g. nanosuspensions) is to improve dissolution and 
bioavailability.  This concept is based on a reduction in particles size, resulting 
in a markedly higher surface area which would lead to noticeably enhanced 
dissolution rate (Zhao et al., 2007) with positive consequences for bioavailability 
(Blagden et al., 2007). These enhanced properties are of particular importance 
for hydrophobic drugs (Langguth et al., 2005), where their poor solubility profile 
adversely affects the rate and extent of drug absorption and associated efficacy.  
Increased dissolution rate and increased saturation solubility has been reported 
(Muller et al., 2001), and with this comes the basic benefits offered by 
nanosuspensions over other conventional dosage forms.  
This point of view is best presented by considering the impact of reduced 
particle size on the following physico chemical parameters: 
  
(1) The Nernst – Brunner and Levich modification of the Noyes - Whitney 
equation (Merisko-Liversidge et al., 2003, Kesisoglou et al., 2007, 
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Patravale et al., 2004) describes the increased dissolution rate with 
increased particle surface area: 
 
                                      (Equation 1.1) 
 
where X is the amount of drug in solution, 
t is time,  
A is the effective surface area,  
D is the diffusion coefficient of the drug,  
  is the effective diffusion boundary layer,  
C is the saturation solubility of the drug, and  
V is the volume of the dissolution medium.  
 
Equation 1.1 shows that dissolution rate is proportional to particle surface area, 
and therefore is expected to improve. 
 
(2) According to Patravale et al. (2004), the increase in the saturation 
solubility of nano - sized particles can be explained by Ostwald - 
Freundlich's equation: 
 
                                         (Equation 1.2) 
 
where Cs is the saturation solubility,  
C  is the solubility of the solid consisting of large particles,  
   is the interfacial tension of substance,  
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V is the molar volume of the particle material,  
R is the gas constant,  
T is the absolute temperature,  
  is the density of the solid, and  
r is the radius. 
 
According to some reports, the saturation solubility of nano-sized particles was 
quantified and found to be higher than that of microparticles (Muller and Peters, 
1998, Muller et al., 1999) and raw material (Dong et al., 2009). Eerdenbrugh et 
al. (2010), however, questioned if the reported increases in saturation solubility 
of crystalline drug particles are due to an actual effect of nanosizing or due to 
artefact resulted from inefficient separation techniques. Moreover, Eerdenbrugh 
et al. reported that increased particle curvature may result in significantly higher 
solubility only for particles with a radius of less than 10nm.  
In summary, reduced particle size resulted in enhanced dissolution rate due to 
the increased surface area (Equation 1.1) accompanied with increased 
saturation solubility of particles (Equation 1.2).  
Hence, the production of medicinal formulations containing nano-sized particles 
of APIs has proven to encompass tremendous advantages over those 
containing micro - and macro - scaled particles. These advantageous properties 
enable nanomedicines to be considered as one of the prioritized applications 
over other available competent choices used for the production of safe and 
effective preparations in pharmaceutical industry.  
In addition, the capability to manipulate the surface properties of nanoparticles 
enables the favourable use of nanosuspensions in drug delivery. The surface 
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manipulation can be undertaken to target specific site of action, including cell 
organelles. Pignatello et al. (2006) have investigated the surface modification of 
nanoparticles for enhanced ocular drug delivery of cloricromene. 
One of the actively explored applications of sub-micron APIs is their formulation 
for parenteral administration. Where the formulation of parenteral 
nanosuspensions has been reported to confer better therapeutic response, 
slower clearance rate and lower toxicity at higher tolerable doses when 
compared to traditional formulations (Merisko-Liversidge et al., 2003) thus an 
efficient and cost-effective therapy is achieved. Nanosuspensions of paclitaxel, 
an anticancer agent, have been reported to exert an enhanced therapeutic 
performance at higher tolerable doses with lower toxicity profile than a 
traditionally-formulated marketed product: Taxol® (Merisko-Liversidge et al., 
2003). 
Following intravenous administration of nanosuspensions, the circulating drug 
nanoparticles are recognized and sequestered by the mononuclear phagocytic 
system (MPS), mainly by the hepatic and splenic macrophages. This uptake 
process may enable the preferential distribution of therapeutic nanoparticles to 
targeted organs (also referred to as natural or passive targeting), as reported to 
be successfully utilized to obtain comparable drug levels in major tissues 
(Kesisoglou et al., 2007) and for prolonged action (Patravale et al., 2004). 
Moreover, Martin et al. (1982) suggested that macrophages may act as drug 
delivery reservoirs of the trapped particles to the site of action.  
On the other hand, surface modifications of parenteral nanosuspensions with 
hydrophilic polymers, such as poloxamer, were reported to be utilized to 
decrease opsonisation (adsorption of plasma proteins to the circulating 
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particles), oppose the uptake by macrophages and subsequently enable the 
alteration of biodistribution and targeting of circulating particles (Storm et al., 
1995, Torchilin and Trubetskoy, 1995, Stolnik et al., 1995). In addition, Moghimi 
et al. (2001) and Gaur et al. (2000) reported that particle size reduction can also 
prolong the circulation times of drug nanocarriers. 
Moreover, the nanopharmaceuticals concept has been successfully recognized 
as a promising solution for some pharmaceutical issues that have been 
considered to be problematic for drug product development. Of particular 
importance is their use to increase the low bioavailability of poorly – water 
soluble APIs (hydrophobic drugs) (Liversidge and Cundy, 1995). This hurdle 
has always been a challenging issue faced by pharmaceutical manufacturers as 
it is estimated that greater than 40% of newly identified active substances 
demonstrate low aqueous solubility (Merisko-Liversidge et al., 2003, Patravale 
et al., 2004, Zhao et al., 2007, Hu et al., 2004). Therefore, nanomedicines are 
proving to be a useful model approach to addressing issues of solubility 
(Matteucci et al., 2006, Dong et al., 2009) and sub-optimal biological 
performance of some promising hydrophobic drugs (Keck and Muller, 2006, 
Rawat et al., 2006). Owing to all these advantageous properties, successful 
uptake of nanoparticles across various biological membranes has been actively 
explored (Vasir and Labhasetwar, 2008, Yacobi et al., 2008, Naha et al., 2010). 
The reported promising findings of nanoparticles trafficking across cell 
membranes have therefore expanded the applications of nanomedicines in drug 
delivery.  
 
 
P a g e 8 Formation and cell interaction of hydrocortisone and prednisolone nanoparticles  
 
1.1.2 Limitations of nanomedicines 
An ongoing significant challenge for the development and implementation of 
nano medicines, that could limit their usage, is the possibility of particle - 
particle aggregation (Mohanraj and Chen, 2006).  This is a critical issue as the 
agglomeration rate is higher as the overall particle size decreases with an 
accompanied increase in surface area.  
Moreover, the presence of a relatively wide distribution of particle size within a 
nanosystem, i.e. the existence of very small and large particles in the same 
dispersion, should be avoided.  This size distribution is indicated by measuring 
polydispersity index (PDI). For a stable nanoparticle dispersion e.g. 
nanosuspension, a narrow size distribution with PDI ranging between 0.1 - 0.25  
is most preferred (Patravale et al., 2004).  High PDI value (greater than 0.5) 
means wide size distribution that can lead to Ostwald ripening and eventually 
compromise the formulation's stability and reduce its expected shelf-life. 
Ostwald ripening arises when the smaller particles start to dissolve and 
disappear with simultaneous size growth of the larger particles. This 
phenomenon mainly occurs due to the different saturation solubilities and 
existence of concentration gradient between the small and large particles 
(Jacobs et al., 2000, Patravale et al., 2004, Muller et al., 2001). The high 
saturation solubility of the fine API particles leads them to dissolve and causes 
the drug concentration to increase and so promotes the growth of larger 
particles. This in turn drives a continuous process leading eventually to an 
increase in the size of the large particles and the disappearance of the fine 
particles. The absence of Ostwald ripening in nanosuspensions would indicate 
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the uniformity of size distribution and reduced differences in saturation solubility 
and concentration gradient between particles.  
Thereby, the use of stabilizers is essential in nanosuspension formulation to 
lower the surface energy of the small particles in order to prevent particle - 
particle agglomeration and crystal growth.   Stabilizers used in nanosuspension 
formulation can be either steric, electrostatic stabilizers or usually combination 
of both. Steric stabilizers (e.g. polyvinylpyrrolidone (PVP), hydroxypropylmethyl 
cellulose (HPMC), poloxamer) tend to arrest particle growth and particle 
aggregation by adsorbing a protective layer around the particles. Alternatively, 
electrostatic stabilization (e.g. Tween 80, sodium dodecyl sulphate (SDS) acts 
by inducing charge repulsion between particles by adsorbing a charged 
molecule on particle surfaces. Thus, for complete stabilization, a combination of 
both stabilizers is commonly used to avoid flocculation within the 
nanosuspension system (Kesisoglou et al., 2007). 
Due to the ability of nanomedicines to affect cellular and molecular biological 
targets, some literature has raised some concerns about possible adverse or 
toxicological effects of nanotechnology, particularly when unintended targets 
are reached and adversely affected (Linkov et al., 2008). These concerns may 
be due to the incomplete knowledge on the fate of nanoparticles after 
administration, whether non-selective biodistribution takes place and how 
inherent risk(s) can be evaluated and controlled. More serious nanotoxicological 
concerns are accompanied with intravenous nanomedicines, in which particle 
size is a determinant factor for tissue distribution (Moghimi et al., 2005).    
Overall, expected adverse effects of administered nanoparticles could be 
minimized by using biocompatible, biodegradable materials and surface 
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modifications to reduce particle accumulation in the liver and spleen (Garnett 
and Kallinteri, 2006). Additionally, available techniques (such as radiolabelling) 
employed to evaluate the distribution of nanomedicines into specific targets 
following administration have been reported (Linkov et al., 2008) which would 
allow monitoring of potential adverse effects of administered nanomedicines in 
the major organs. 
 
1.1.3 Types of nanoparticles 
Overall,  classification of nanoparticles is dependent on the composition and 
phase of the components,  whether a solid, liquid or gas material was employed 
to generate the overall macroscopic phase state of the nano system at room 
temperature (Husseini and Pitt, 2008). The aim of the present work was to 
produce solid drug nanoparticles dispersed in stabilized liquid acting as 
nanocarriers of a drug with low aqueous solubility.  
 
1.1.3.1 Solid state nanoparticles 
As defined in Section 1.1.3, solid nanoparticles are nanosystems composed of 
a solid state material in the core at room temperature. Solid state nanoparticles 
are divided into polymeric and non - polymeric nanoparticles (Husseini and Pitt, 
2008). Both types can be distinguished by the presence of a polymer. In 
polymeric nanoparticles, a drug is enclosed in a biodegradable and 
biocompatible polymeric core. Examples of polymeric nanoparticles include: 
hydrogel nanoparticles and polymeric micelles. Non – polymeric nanoparticles 
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are mainly composed of pure drug nanoparticles surrounded by a layer of 
surfactants i.e. in these nanoparticles, the drug moiety itself behaves as the 
carrier. 
 
1.1.4 Production of nanosuspensions 
Nanosuspension preparation methods can be divided into two principle routes 
either top - down or bottom - up approaches (Figure 1.1). The principle of each 
method is derived from the respective name, and each has its own advantages 
and hurdles.  
(i) The top-down method. It involves the physical comminution of the drug 
crystals into nano-sized particles by dry or wet milling techniques. It involves 
particle size reduction to form nano-sized particles from coarser starting 
materials. The recent development of comminution technologies provides a 
range of approaches for reducing the size of different materials. Top-down 
technologies include: media milling, microfluidization and high pressure 
homogenization (Verma et al., 2009, Keck and Muller, 2006). On the other 
hand, this suite of approaches demonstrates a number of limitations and 
drawbacks. These size reduction processes apply high energy forces and 
stresses to the material, which have the potential to induce degradation of 
thermally labile compounds, whilst also facilitating the transformation of physical 
form for those compounds which are subject to polymorphism, and may 
introduce impurities (Matteucci et al., 2006, Verma et al., 2009).  Moreover, 
attempts to reorder these crystal defects and to re-crystallize amorphous 
regions have resulted in both physical and chemical instability of the processed 
materials on storage (Verma et al., 2009). 
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(ii) The bottom-up method. This method's principle is based on controlled 
precipitation of drug nanoparticles from a dissolved form in a suitable solvent 
upon the addition of an anti-solvent containing selected stabilizers. Bottom-up 
approaches avoid pitfalls encountered with high pressure milling or 
homogenization techniques. Four major bottom-up approaches are employed to 
prepare nanoparticles: (i) solvent – anti-solvent method; (ii) supercritical fluid 
technology; (iii) spray drying; and (iv) emulsion – solvent evaporation (Verma et 
al., 2009, Li et al., 2007). This project focused on the solvent - antisolvent 
precipitation approach in a Y – shaped micro channel reactor. The advantages 
of this approach include its simplicity, low cost and possible scale-up (Dong et 
al., 2009). In addition, the ability to control the size and surface properties of the 
formed particles is possible through manipulating the processing parameters 
such as solution flow rates, internal diameter of the reactor, the initial drug 
concentration of solution and inclusion of surface modifiers (Zhao et al., 2007, 
Brook, 2006) .  This approach is based on driving rapid supersaturation which 
results in precipitation of drug nanoparticles from its dissolved form in organic 
solvent using an antisolvent (usually an aqueous solution of stabilizers). In anti-
solvent precipitation technique, the miscible organic solvent tends to diffuse into 
the aqueous phase and spread the newly precipitated nuclei apart, and thereby 
enhances the stabilization of the formed nuclei (Matteucci et al., 2006).  On the 
other hand, the main challenge faced by this method is the need to control the 
crystal growth using surfactant(s) (Keck and Muller, 2006). Also, during the 
process of crystallisation, unstable polymorphs and solvates can be formed 
providing difficulties of complete removal of the used organic solvent (Verma et 
al., 2009). The application of bottom-up methods have some limitations and 
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require additional development before becoming commercially applicable for 
marketed production scales. For instance, the use of precipitation methods 
necessitates the drug to be soluble in at least one solvent which is miscible with 
an appropriate anti-solvent. This condition may exclude the formulation of APIs 
with low solubility in aqueous and organic media (Muller et al., 2001). 
 
Figure 1.1 Diagram summarizes different methods for preparation of 
nanoparticles 
 
Top Down method                                                                Bottom up method                                   
1.1.4.1 Microfluidic reactors 
Microfluidic reactors or microchannel reactors (MR) are reactors composed of 
micrometer - sized channels. Owing to their dimensional properties, MR have 
attracted great attention recently as they allow the introduction of small amounts 
of fluids which can be mixed efficiently due to the created large interfacial 
surface area within the channel diameter. This leads to efficient mixing over 
Size reduction 
of coarse drug 
particles 
Nanoparticles 
Addition of 
aqueous 
phase to drug 
solution in 
organic 
solvent 
Incorporation 
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reasonably short periods of time. MR design and applications have experienced 
rapid advances recently and are used for multiple purposes (Aubin et al., 2010, 
Adeosun and Lawal, 2010) since they were first introduced in early 1990's 
(Brook, 2006). Among the many applications of microfluidic reactors in modern 
pharmaceutics, synthesis of pharmaceutical nanoparticles with great control of 
particle size, morphology, composition and size distribution is an additional 
recent one (Marre and Jensen, 2010). Zhang et al. (2010) have recently 
reported examples of various organic, inorganic and biological nanoparticles 
that were synthesized using MR. The wide range of flow rates (from sub ml/hour 
up to 10-10.000 l/hour) through which fluids can be introduced to the different 
available designs of micromixers, confers their potential broader applications in 
chemical analysis and production (Hessel et al., 2005).  
In order to obtain drug crystals from the fluid stream passing throughout the 
channels, the following stages need to take place before precipitation occurs: (i) 
solute supersaturation (ii) nucleation (iii) crystal growth and (iv) aggregation. 
Supersaturation is the driving force for a precipitation to occur, and its rate can 
be controlled by manipulating the flow rates by which the solvent and anti 
solvent enter the reactor. Zhao et al. (2007) reported the achievement of  
instant supersaturation by modifying the solvent/anti-solvent ratios. 
When both drug solution (solvent) and an anti-solvent (another solvent in which 
the drug is insoluble in) are introduced through the reactor inlets, the drug 
reaches supersaturation state as soon as the dissolved drug molecules (solute) 
are rapidly mixed and come in contact with the anti – solvent. The nucleation 
phase (a phase in which a crystal is newly formed) then commences (Aulton, 
2009), for which the time is dependent on the degree of reduction in solute 
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concentration.  To obtain a narrow particle size distribution, the nucleation step 
should take place rapidly to prevent further nucleation and prevent particle 
aggregation (Zhang et al., 2010). 
There are different configurations of micromixers. The one of interest in the 
present study was the Y - shaped microchannel reactor (Figure 1.2).  
 
Figure 1.2 Y- shaped microchannel reactor  
 
    
 
 
There are a number of suggested mechanisms of mixing operation associated 
with the MR approach (Aubin et al., 2010). Some of these are hypothetical and 
involve complex fluid dynamics and details that are not suitable for exploration 
in this thesis. Nevertheless, in regards to nanoprecipitation, it is essential to 
point out that efficient fluid mixing within the microfluidic system is essential for 
good crystallization. Also it is important to consider all factors - mainly related to 
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the design of MR- affecting particle precipitation within micro reactors.  These 
factors include: length of channels, collision angle of fluids and internal diameter  
(Aoki and Mae, 2006) and fluid flow rates .    
   
1.1.4.2 Nanoparticle coating 
The ability to modify the surface properties of a nanoparticle is one of the 
numerous advantages offered by these systems. Among nanoparticle coatings, 
the use of lipids (Brook, 2006, Mehnert and Mader, 2001), cationic surfactants 
(Al-Thabaiti et al., 2008) or even both to form cationic solid lipid nanoparticles 
(Montana et al., 2007) have been reported. 
Coating nanoparticles with lipids to form solid lipid nanoparticles (Hu et al., 
2002) and with cationic surfactants (Peetla and Labhasetwar, 2009) for use for 
controlled drug delivery, to enhance in vitro and in vivo efficacy of nanoparticles, 
has previously been investigated. 
 
1.1.5 Characterization of nanoparticles 
1.1.5.1 Particle size 
Particle size and size distribution are the main characteristics which determine 
the stability and performance of nanosuspensions. Both parameters govern the 
dissolution and physical stability of nanosuspensions. Particle size also affects 
the nanoparticle-cell interaction, determining the extent of cellular uptake 
(Panyam and Labhasetwar, 2003) and the route of penetration of nanoparticles 
across biological membranes (Garnett and Kallinteri, 2006). Particle size can be 
typically determined by measuring the Brownian motion of the particles in the 
sample using dynamic light scattering (DLS). Brownian motion refers to the 
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continual movement which small colloidal particles undergo (Hunter, 1993).  
DLS is used for rapid and accurate determination of particle size. In addition, 
DLS can also be used to measure polydispersity index (PDI) that indicates the 
width of size distribution of nanoparticles within nanosuspensions. PDI values 
should be as low as possible to achieve maximum physical stability of 
nanosuspensions through reduction in potential for Ostwald ripening.  It is 
generally acknowledged that PDI values of 0.1 – 0.25  (Patravale et al., 2004) 
would indicate an acceptably narrow particle size distribution.   
Laser diffractometry analysis (LD) is also carried out to determine contamination 
of nanosuspensions with microparticles or the presence of nanoparticle 
aggregates. 
 
1.1.5.2 Surface charge -potential) 
Particle's surface charge is one of the characteristic parameters of a 
nanosuspension and is measured as Zeta-potential (-potential). -potential of a 
nanosuspension is a function of the stabilizer and the drug itself, and it 
measures the stability of the colloidal system.  Surface charge measures the 
difference in potential that exists between the particle's surface and the Shear 
plane (Figure 1.3), and its measurement is based on electrophoresis by 
assessing the charged particle mobility in the suspending liquid under an 
applied electric field. The electrophoretic mobility (the speed of particle's 
movement in electric field) is a function of: -potential, electric field strength, 
viscosity and the dielectric constant of the medium. These parameters are 
interrelated by Henry's equation (Aicart et al., 2006, Agnihotri and Vavia, 2009): 
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                                                                       (Equation 1.3)  
              
 
Where  is zeta-potential,  
  is viscosity,  
UE is the electrophoretic mobility, 
  is the dielectric constant, and 
f a) is Henry's function. 
 
 (the Debye length) is reciprocal length, and k-1 is frequently taken as a 
measure of the electrical double layer thickness. Therefore, f a) factor 
depends on the particle radius (a) and  the thickness of the electrical double 
layer (-1).  
The DVLO theory (by Derjaguin, Verwey, Landau and Overbeek) suggests that 
the stability of a colloidal system is determined by the sum of the van der Waals 
forces of attraction and electrical double layer repulsive forces that exist when 
particles approach each other due to the Brownian motion (Florence and 
Attwood, 2006).  
-potential is one of the measured characteristics of a colloidal system which 
indicates its potential long term stability. For electrostatically stabilised 
nanosuspensions, -potential is generally accepted to be within the range of ± 
20 - 30 mV, whereas -potential of ± 20 is desirable for suspensions which are 
stabilized solely through steric mechanisms (Patravale et al., 2004, Muller et al., 
2001). However, higher -potential values of fairly stable nanosuspensions 
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(lying outside this range) were also reported (Varshosaz et al., 2009, Peetla and 
Labhasetwar, 2009) 
 
 
Figure 1.3 Schematic representation of distribution of charges at the surface of 
a negatively charged solid particle. Where 0 is the surface potential,  the 
potential at the Stern plane,  the zeta potential and 1/ the thickness of double 
layer (Florence and Attwood, 2006) 
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1.1.5.3 Ultraviolet-visible spectroscopy (UV-Visible spectroscopy) 
UV-Visible spectroscopy is widely used for quantitative analysis of broad range 
of chemical and biological substances. The quantification is based on Beer-
Lambert law (Equation 1.4), where the measured absorbed light (absorbance) is 
quantitatively related to the product of concentration (c) of analyte in the sample 
and the pathlength (l) of the cell (Thomas, 1996): 
 
                                                                      (Equation 1.4) 
 
Where A is the absorbance,  
a is absorptivity (a proportionality constant),  
c is the concentration of absorbing substance, and 
l is the cell pathlength. 
 
1.1.5.4 Transmission electron microscopy (TEM) 
The high resolution of the transmission electron microscope makes it an 
essential tool for size and morphological characterization of nanoparticles. Its 
principle is based on focusing a very thin beam of electrons that travels through 
the specimen. Depending on the specimen's density, electrons are absorbed or 
scattered, and the remainder are transmitted (Hunter, 1993). The transmitted 
electrons will eventually give rise to a magnified image of the specimen that can 
be photographed by an attached camera. 
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1.1.5.5 Differential scanning calorimetry (DSC) 
Differential scanning calorimetry is a technique that measures the thermal 
profile of the test sample.  It measures the energy absorbed by the sample to 
maintain the same temperature as a parallel reference, when both sample and 
a reference are subjected to same controlled thermal conditions (Laye, 2002).  
 
1.1.5.6 Powder X-ray diffraction (PXRD) 
This technique is useful for structural identification of crystal pattern of 
materials, and it indicates the atomic plane spacing within the crystal lattice. 
When X-ray is targeted towards the sample, the electrons of the material absorb 
the directed X-ray and then scatter it producing a diffracted ray. Sample is 
scanned at different range of angles and so all possible scattered X-rays are 
recorded. The angle of diffraction would only depend on the interatomic 
distances in the crystal (Jenkins and Snyder, 1996).  
The condition in which the wavelength of the radiation is comparable to 
interatomic spacings between the scattering centres in the lattice is described 
by Bragg's law, which states the essential conditions that must be satisfied for a 
diffraction to occur (Cullity and Stock, 2001): 
  
                                                                         (Equation 1.5) 
 
where n is the order of diffraction,  
  is the wavelength of the X-radiation,  
d is the interplanar distance, and 
  is the diffraction angle 
P a g e 22 Formation and cell interaction of hydrocortisone and prednisolone nanoparticles  
 
Processing and counting the scattered X-ray reflect the crystal pattern of the 
material and characteristic X-ray spectra are produced for interpretation. 
 
1.1.6 Applications of nanopharmaceuticals 
The current applications of nanomedicines cover a relatively wide spectrum of 
the medical field, and have great potential to open up new opportunities for 
improved drug delivery strategies. The ability to formulate nanopharmaceuticals 
for administration by nasal (Keck and Muller, 2006), ocular (Calvo et al., 1996), 
oral  (Muller et al., 2001), parenteral  (Dufresne et al., 2004, Muller and Peters, 
1998) and pulmonary (LaVan et al., 2002) routes is continued to be extensively 
investigated and some are already a current reality. These include the usage of 
nanopharmaceuticals as diagnostic (imaging), therapeutic (drug delivery and 
treatment), and in vivo drug monitoring agents.  Therapeutic applications of 
drug nanocarriers include their use in treatment of tumours (Dufresne et al., 
2004), chronic hepatitis (Thomas and Foster, 2007), gene delivery (Csogor et 
al., 2003) and drug delivery to brain (Mohanraj and Chen, 2006, Kreuter et al., 
2003). The application of nanomaterials in oncology is collectively known as 
cancer nanotechnology, where they are actively used in the prognosis, 
diagnosis and treatment phases of the disease (Ferrari, 2005).  
Nanomaterials also have diagnostic imaging applications that have previously 
been investigated (Sahoo and Labhasetwar, 2003, Farokhzad and Langer, 
2006a). 
In all these uses, drug nanosystems (nanomedicines) were either uncoated or 
coated nanoparticles, nano-encapsulated systems (Zahr et al., 2005), 
liposomes, nanoshells, dendrimers, polymers, micelles, quantum dots or 
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magnetic nanoparticles (Sahoo and Labhasetwar, 2003, Garnett and Kallinteri, 
2006).  The potential use of nanoparticles as transdermal vaccines has also 
been studied (Kohli and Alpar, 2004). 
 
1.1.7 Nanosuspensions of steroid drugs 
Preparation of nanoparticles of some poorly water-soluble steroid drugs has 
been reported in literature. The main aim of preparing these drugs as nano-
sized particles was to enhance their dissolution and solubility properties, and 
consequently their bioavailability. Improved solubility and dissolution profiles of 
nanosized spironolactone and prednisolone formulated with different 
nanonization methods was reported (Dong et al., 2009, Muller and Peters, 
1998). Also, Hany et al. (2009b) has reported the preparation of stable 
hydrocortisone nanosuspensions.  
In this study, the preparation of two drug nanoparticles of the same 
pharmacological group has been undertaken. The downstream processing of 
nanoparticles has however been tuned to provide modification of surface 
charge. 
 
1.1.7.1 Hydrocortisone and prednisolone 
Hydrocortisone and prednisolone are corticosteroids with predominant 
glucocorticoid and to a lesser extent mineralocorticoid activities. However, 
prednisolone exerts less mineralocorticoid activities than hydrocortisone 
(Martindale: The complete drug reference, 2009, British National Formulary, 
2010). 
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1.1.7.1.1 Physico-chemical properties 
Hydrocortisone (Figure 1.4.i) is practically insoluble in water (>10.000 ml/g) and 
sparingly soluble in alcohol (30-100ml/g). While prednisolone (Figure 1.4.ii) is 
very slightly soluble in water (1000-10.000 ml/g) and soluble in alcohol (10-30 
ml/g) (British Pharmacopoeia, 2008). 
 
Figure 1.4 Molecular structures (in two dimensions) and nomenclature of (i) 
hydrocortisone and (ii) prednisolone 
 
 
(i ) Hydrocortisone (11, 17 , 21–Trihydroxypregn-4-ene-3,20-dione) 
 
Chemical formula: C21H30O5    
Molecular weight: 362.5  
 
 
(ii) Prednisolone (11, 17 , 21–Trihydroxypregna-1,4-diene-3,20-dione) 
 
Chemical formula: C21H28O5       
Molecular weight: 360.4  
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As shown in Figure 1.4, the chemical structures of both drugs are similar, 
except the presence of an additional double bond in prednisolone in position 
1,2. This modification increases the glucocorticoid activity nearly fourfold than 
that of hydrocortisone, also results into slower metabolism of prednisolone 
(Brunton et al., 2006).  
 
1.1.7.2 Pharmacokinetics 
Hydrocortisone and prednisolone are readily absorbed from the gastrointestinal 
tract (GIT), where the dissolution rate is a limiting step for the bioavailability of 
prednisolone. Plasma half – lives of hydrocortisone and prednisolone are 
approximately 100 minutes and 2 - 4 hours, respectively. Prednisolone is 
extensively bound to plasma proteins, although less than the 90% protein 
binding observed for hydrocortisone (Martindale: The complete drug reference, 
2009).  Hydrocortisone is absorbed through the skin, and is mainly metabolised 
in the liver and its metabolites are excreted in the urine mainly as the 
glucuronide conjugate, with a very small proportion as the unchanged form 
(Martindale: The complete drug reference, 2009). Prednisolone however is 
excreted in urine as free and conjugated metabolites, with a significant 
proportion excreted as unchanged prednisolone (Martindale: The complete drug 
reference, 2009).  
 
1.1.7.3 Pharmacological uses 
Hydrocortisone has a number of clinical indications owing to its glucocorticoid 
action, with the most common uses related to its anti - inflammatory and 
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immunosuppressant properties. Its main medical indications include: 
replacement therapy in adrenal insufficiency, asthma and topical inflammatory 
conditions (British National Formulary, 2010). Medical uses of prednisolone are 
similar to those of hydrocortisone. However, prednisolone is preferred for long - 
term disease suppression due to its less mineralocorticoid activity (British 
National Formulary, 2010).  
Hydrocortisone and prednisolone are available in a range of dosage forms for 
oral, ophthalmic, otic and rectal routes of administration. Parenteral and topical 
hydrocortisone preparations are also available (British National Formulary, 
2010). 
 
1.1.7.4 Relative potency 
It is estimated that equivalent doses of hydrocortisone and prednisolone needed 
to exert the same glucocorticoid (anti – inflammatory) effect are 5mg and 20 
mg, respectively (Brunton et al., 2006, Martindale: The complete drug 
reference, 2009). Hence, prednisolone is about four times more potent than 
hydrocortisone. 
Successful preparation of nanomedicines of hydrophobic drugs such as 
hydrocortisone and prednisolone (drugs with low-aqueous solubility and high 
permeability profile) has been reported in the literature (Kesisoglou et al., 2007, 
Ali et al., 2009b, Muller and Peters, 1998). However, a considerate thought 
should be given to the biopharmaceutical properties and the possible route(s) of 
administration of the final nanoformulation of APIs. Muller and Peters (1998) 
reported that nanosizing poorly-water soluble drugs would allow their use for 
non-oral drug delivery including parenteral and local administration, with 
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expected promoted dissolution of nanoparticles in the blood and at the site of 
administration.     
The same concept can be possibly applied on hydrocortisone and prednisolone, 
two poorly - water soluble drugs with high permeability properties. Therefore, 
the formulation of nanosuspensions of such APIs would address the low 
solubility issue, enhance dissolution and is therefore expected to expand their 
use as local sustained-release drug carriers to specific sites of action, (mainly 
mucosal surfaces, such as ocular, nasal and pulmonary drug delivery) for better 
therapeutic performance than conventional forms (Pignatello et al., 2006, 
Alonso, 2004, Patravale et al., 2004). However, although the use of 
nanoparticulates is aimed at improving dissolution, for hydrophobic APIs, it is 
probable that undissolved particles will reside for prolonged times at the site of 
administration, particularly where small volumes of fluid are available, for 
example in nasal and ocular dosage forms (Muller et al., 1999, Keck and Muller, 
2006).  Knowledge of the biological fate of undissolved nanoparticles is 
therefore essential to provide an in depth understanding of the safety and 
efficacy of these medicines. 
Therefore, the aim of the current work was to study the preparation of 
nanosuspensions of these two hydrophobic APIs to determine whether they 
were able to achieve an improved anti-inflammatory effect over each drug in 
solution form.  
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1.2 Cell – drug interaction 
 
As previously discussed in Sections 1.1.1 and 1.1.6, efficient drug delivery is 
one of the main applications of nanomedicines. Hence, it is essential to 
overview the possible cell - drug interaction mechanisms by which the 
nanomedicines can improve the delivery of drugs with low aqueous solubility.  
 
1.2.1 General Introduction 
Drugs can act by activating cell receptors in order to exert their pharmacological 
action. Cellular receptors are important elements for the functional 
communication between different cells throughout body systems. Cellular 
receptors are generally classified into four groups, these are:  
 
 G protein - coupled receptors 
 Tyrosine kinase receptors 
 Receptor – operated channels  
 DNA  -  coupled receptors 
 
The G protein consists of three subunits (   and ) and is located in the cell 
membrane. G protein – coupled receptors remain inactive in the absence of 
agonist, and get activated once an agonist binds to the receptor, and this 
eventually leads to response through a number of events (Page et al., 2006). 
Tyrosine kinase receptors are involved mainly in events controlling growth and 
cell differentiation. Binding agonists cause the receptor to act as a tyrosine 
kinase enzyme that phosphorylates tyrosine residues , allowing them to act as 
high-affinity sites for intracellular proteins (Page et al., 2006).  
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Receptor - operated channels are composed of five subunits, termed two      
and   subunits Channels are either open, close or close-but-openable to an 
appropriate stimuli when are activated, inactivated or rested, respectively (Page 
et al., 2006). 
DNA – coupled receptors belong to the nuclear receptor family that are 
composed of 40 intracellular receptors. The receptors are generally categorized 
according to their cellular location into two main groups: those present in the 
cytoplasm or in the nucleus. The pharmacological actions of steroid hormones 
and glucocorticoids are mainly mediated via DNA – coupled receptors (Rang et 
al., 2007). 
For drugs that interact with cytoplasmic or nuclear receptors, their transport into 
the cell (endocytosis) is important. Endocytosis is the process that describes the 
internalization of extracellular ions, molecules and/or organic compounds into 
the cell through the cell membrane. There are different possible mechanisms by 
which extracellular substances (including drugs) can cross through cell 
membranes to exert their intracellular effect (Katzung et al., 2009).   
Endocytosis of substances into cells can take place by either passive, active or 
receptor - mediated pathways. 
Passive diffusion is in turn divided into simple and facilitated pathways. Both 
passive transport mechanisms (either simple or facilitated diffusion) do not 
involve energy input to allow ions and organic compounds to pass. In contrast, 
facilitated diffusion, ions and organic compounds require a transporter to pass 
through the cell membrane into the cell. Passive diffusion is the dominant 
transport route of most drugs (Brunton et al., 2006). Active transport requires 
energy input, and it plays an important role in the uptake and efflux of drugs and 
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other solutes.  According to a recent classification, endocytosis can generally be 
divided into pinocytosis and phagocytosis (Sahay et al., 2010). Pinocytosis (as 
a receptor - mediated cell internalization mechanism) is the uptake of fluids and 
solutes into the cell. According to Sahay et al. (2010), pinocytosis can be 
classified, based on the type of protein involved in the initial uptake of particles 
and solutes, into 2 main pathways:  (i) clathrin - dependent endocytosis and (ii) 
clathrin – independent endocytosis. Clathrin - independent endocytic pathway is 
further subdivided into macropinocytosis, caveolae – mediated and caveolae - 
and clathrin-independent endocytosis.  
Phagocytosis describes the process of cell uptake of larger particles and 
proteins forming a phagosome which enters the cell for further lysis or digestion 
with cell organelles. Alternatively, it can even be expelled from the cells, after 
processing (exocytosis). Phagocytosis is observed with specialized cell types 
(phagocytes) e.g. macrophages and monocytes.  
In order to control or enhance the cellular uptake of substances into the cell, a 
careful consideration should be given to the physicochemical properties of the 
particles desired to translocate a cell membrane and type of cell.  Firstly, it is 
the particle's degree of hydrophobicity.  As the particle's hydrophilic or 
hydrophobic affinity determines its penetration route across the cell membrane. 
Due to the lipophilic nature of the biological cell membranes (mainly composed 
of bilayer phospholipids and proteins), the more hydrophobic the material is, the 
more the tendency to follow passive diffusion to pass into the cell. Hence, it is 
expected that hydrophobic materials would permeate through cell membranes. 
Secondly, size of particles may control the route by which a substance can be 
transported across a cell membrane. It is reported that some large molecules    
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(as large as molecular weight of 30.000 ) can pass by diffusion to some tissues 
(Katzung et al., 2009). Therefore, the appropriate route(s) of administration 
should be considered based on the physico-chemical properties of the 
administered medicament in order to achieve optimum pharmacological effects.  
 
1.2.2 Cellular uptake of nanoparticles 
As described in Section (1.2.1), a number of influencing factors may adversely 
affect the successful endocytosis of therapeutic agents, mainly the physico-
chemical properties and the size of the crossing particles. Thereby, cell 
internalization of some APIs by nanocarriers would be highly advantageous 
(Panyam and Labhasetwar, 2003). Vasir and Labhasetwar (2008) reported that 
the use of nanocarriers to enhance the intracellular transport of medicinal 
agents has been widely explored. However, it is important to understand the 
mechanism by which these nanocarriers interact with cell membranes, as well 
as applying the appropriate technique(s) to assess that interaction.  There are a 
limited number of suggested mechanisms for cell internalization of 
nanomedicines. However, caveolae – mediated endocytosis has gained a great 
attention as is reported to be the pathway responsible for cell delivery of several 
nanomaterials (Sahay et al., 2010). Caveolae are described as flask-shaped 
membrane invaginations, forming what resembles vesicles that mediate some 
endocytosis and transcytosis processes. The shape of caveolae is due to the 
presence of a number of proteins, mainly caveolin. This shape formation allows 
caveolae to engulf molecules that attach to its surface. Caveolae are abundant 
in variety of cell types e.g. muscles, fibroblasts and adipocytes (Sahay et al., 
2010, Mukherjee et al., 1997).  A limited number of nanocarriers have been 
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reported to pass cell membranes by caveolae- and clathrin-independent 
endocytosis (Sahay et al., 2010).   A relatively recent mechanism that has been 
identified to transfer molecules (including nanoparticles) through cell 
membranes into cell is by linking them to peptides to facilitate their cell 
translocation (Gupta et al., 2005).  These peptides are known as cell 
penetrating peptides (CPP) (Gupta et al., 2005, Torchilin, 2006, Richard et al., 
2003). TAT, Antp and transportan are recognized examples of CPPs (Tseng et 
al., 2002, Gupta et al., 2005, Brooks et al., 2005, Torchilin et al., 2001, Torchilin, 
2006). Sahay et al. (2010) have previously investigated the possible cell 
internalization pathways for two FDA (Food and Drug administration) - approved 
anti-neoplastic nanomedicines: Doxil® (doxorubicin hydrochloride) and 
Abraxane® (paclitaxel).  Intracellular delivery of nanoparticles depends on the 
physico-chemical characteristics of those nanoparticles (e.g. particle size, 
morphology, surface properties, etc.) as well as on the nature of the cell 
membrane (Sahay et al., 2010, Peetla and Labhasetwar, 2009, Peetla and 
Labhasetwar, 2008). The impact of particle size and surface characteristics is 
described in Sections 1.2.2.1 and 1.2.2.2.  
 
1.2.2.1 Effect of the particle size 
The nano-scaled diameter of nanoparticulates confers an extra advantageous 
dimension for targeted cellular and tissue drug delivery owing to their sub-
cellular size. Panyam and Labhasetwar (2003) reported a number of findings 
showing the impact of particle size on cellular uptake of particles (ranging from 
2.5 - 250 folds higher uptake) in various cell types.  
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It is clear from these studies that the size of penetrating particles plays a role in 
determining the transport route through biological membranes. Cell uptake of 
large particles (diameter of 0.25-10m) is believed to occur by phagocytosis, 
the various pinocytosis routes were however reported to mediate the transport 
of smaller particles (up to 300nm) (Garnett and Kallinteri, 2006). However, 
according to Sahay et al. (2010), particles of some materials sized up to 5m,  
may also enter cells via pinocytosis. In addition, particle size affects drug 
release from nanoparticles, where faster drug release is associated with smaller 
particles (Mohanraj and Chen, 2006). Moreover, beside the enhanced cellular 
uptake of nanosized particles, they also reduce risks of inducing inflammatory 
responses as reported with microparticles in arterial cells (Panyam and 
Labhasetwar, 2003). 
  
1.2.2.2 Effect of the particle surface properties 
Particle surface properties such as the degree of hydrophobicity and surface 
charge have an effect on particles interaction with cells. Gessner et al. (2000) 
stated that the hydrophobicity of drug carriers affects their in vitro interaction 
with cells. Also, the charge of a particle has great effect on particle- cell 
membrane interaction, with reports suggesting that positively – charged 
nanoparticles demonstrate improved cell penetration profile (Torchilin, 2006) 
over neutral or negative particles (Peetla and Labhasetwar, 2009).  Sahay et al. 
(2010) reported that positively – charged nanoparticles mainly enter cells via 
clathrin – mediated endocytosis.   
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1.2.2.3 Imaging of cellular uptake of nanoparticles 
As mentioned previously in Section 1.2.2 and in order to assess the intracellular 
delivery of nanoparticles, it is important to employ the appropriate imaging 
technique(s) to visualise the delivery process outcomes. Confocal laser 
scanning microscopy (Ernst et al., 2010, Naha et al., 2010) and transmission 
electron microscopy (Win and Feng, 2005) were employed for imaging the 
nanoparticle – cell interactions. For electron microscopy cell imaging, the 
preparation protocol of cell specimens is important phase for good imaging. 
Generally, biological specimen preparation for electron microscopy involves the 
following preparatory steps (Glauret and Lewis, 1998): 
 
1. Cell fixation 
2. Dehydration 
3. Embedding 
4. Sectioning and staining 
 
Cell fixation aims at preserving cell structure after cell death and acts by 
"freezing" the cellular morphological and structural details on contact with the 
fixative solution. Therefore, it is important to retain cell conditions as neutral as 
possible to prevent any changes in cell morphology as a response to 
unexpected factors. Hence, pre-controlled temperature and pH of the fixative 
solution are important factors to obtain a representative image of cells. Cell 
fixation is achieved via a two step process. Cells are initially fixed by the use of 
aldehyde(s) in buffer solution. Mixtures of glutaraldehyde and formaldehyde 
fixatives are the most preferred fixation protocols in modern electron 
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microscopy. Following fixation, the cells are post fixed in osmium tetroxide. 
Osmium tetroxide is widely used for post-fixation of biological specimens 
because it functions as an electron dense stain enabling the visualization of 
ultrastructural cellular details. The aim of cell dehydration is to dehydrate the 
specimens before using the water-immiscible embedding media. The 
dehydration step involves taking the fixed cell specimens through a series of 
solutions at ascending concentrations of the dehydrating agent (mainly ethanol 
or acetone) in water. Afterwards, embedding process aims to replace the 
dehydrating agent(s) in cell specimens with a resin that can be then 
polymerized to form a solid block with acceptable sectioning. Acrylic and epoxy 
resins are the most commonly used embedding media to infiltrate fixed and 
dehydrated specimens. Specimen blocks are then sectioned and stained. 
Uranyl acetate is commonly used for staining specimens prepared for electron 
microscopy, and it shows good contrast of cellular membrane and organelles 
due to the highly electron density of uranyl group. Specimens are then 
examined and imaged with TEM.  
 
1.2.3 Cellular uptake in HaCaT keratinocytes 
The use of HaCaT (Human adult low calcium temperature keratinocytes) cell 
line as a dermal model to study the drug delivery and/or cytotoxicity of API has 
been reported in literature (Naha et al., 2010, Ernst et al., 2010). The 
effectiveness of using HaCaT cell line in the current study was however to act 
as a representative tool to evaluate the uptake of drug nanoparticles by a 
human cell line, with the aim for their application for potential wider drug 
delivery routes for hydrophobic nanomedicines as discussed in Section 1.1.6 , 
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and not only via topical route. Cell internalization of poly N-isopropylacrylamide 
nanoparticles (Naha et al., 2010)  and cyanidin - a non-glycosylated 
anthocyanidin and potential skin protective phytochemical agent - (Ernst et al., 
2010) in HaCaT cells have been recently reported.  
 
1.2.4 Mechanism of action of glucocorticoids 
Glucocorticoids are highly lipophilic and enter the cell mainly by passive 
diffusion (Leung and Bloom, 2003, Chen and Farese, 1999, Katzung et al., 
2009). Intracellularly, glucocorticoids act by binding to steroid - nuclear 
receptors (Page et al., 2006) regulating the expression of target genes. 
Glucocorticoid receptors belong to the nuclear (DNA – coupled) receptors 
family, and they are predominantly present in the cytoplasm in an inactive form 
until binding to glucocorticoids (Brunton et al., 2006). 
Glucocorticoids diffuse passively across the cell membranes, bind to the 
receptor in the cytoplasm forming a glucocorticoid-receptor complex (Page et 
al., 2006, Brunton et al., 2006). Ultimately the glucocorticoid-receptor complex 
translocates into the nucleus and gene transcription commences. As a 
consequence of this time – consuming process of targeted – gene transcription, 
most glucocorticoid effects are manifested over long periods (Brunton et al., 
2006). However, recent studies suggest that some faster biological responses 
of glucocorticoids, that may appear from seconds up to an hour or so, may be 
mediated via activation of membrane - bound receptors (Norman et al., 2004, 
Chen and Farese, 1999). 
Hydrocortisone and prednisolone (which are considered to belong to BCS class 
II drugs) are good examples to be considered for nanoformulation production 
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(owing to their low aqueous solubility) for administration to small-volume topical 
biological targets e.g. nasal, ocular or respiratory, whereby increases in surface 
area have the potential to enhance dissolution. However, there is probability 
that some these particles will remain undissolved at the administration site and 
therefore there is need to assess the interaction of these particles in situations 
simulating the route of delivery.  
Their preparation in nanometer-ranged particles would address the low 
aqueous solubility issue associated with this class of drugs, and make drug 
particles available for interaction and possibly uptake by biological membranes.  
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1.3 Aim of the work 
 
 
The aim of this project was to prepare drug nanoparticles of hydrocortisone and 
prednisolone steroid drugs as examples of hydrophobic APIs. Surface 
modification of those drug nanoparticles was carried out in order to obtain 
positively – charged steroid nanoparticles for cell transduction studies.  
The overall objective of the present study was to develop a HaCaT cell model 
for lipopolysaccharide (LPS) - induced inflammation, and consequently to 
evaluate and compare the anti - inflammatory effect of prepared hydrocortisone 
and prednisolone nanoparticles as an indicator for the nanoparticle-cell 
interaction. The study aimed to examine the anti – inflammatory effect of 
positively - charged coated hydrocortisone and prednisolone nanoparticles and 
compared to that of uncoated nanoparticles. 
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CHAPTER II 
 
MATERIALS  
AND METHODS 
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2.1 Synthesis of drug nanoparticles  
2.1.1 Materials 
All materials used for the production of both coated and uncoated 
hydrocortisone and prednisolone nanoparticles are listed in Table (2.1). All 
materials were used as purchased without any additional purification. 
 
Table 2.1 List of materials and solvents used, and their supplier: 
 
No Name Supplier 
1.  Hydrocortisone  98% Sigma - Aldrich 
2.  Prednisolone 99% Sigma - Aldrich 
3.  Hydroxypropylmethyl 
cellulose (HPMC) 15 cPs 
Shin Etsu 
4.  Polyvinylpyrolidone K 30 
(PVP) 
Sigma - Aldrich 
5.  Sodium dodecyl sulfate 
(SDS) > 99.0 % 
Sigma - Aldrich 
6.  Cetyltrimethylammonium 
bromide (CTAB) ≥ 99.0 % 
Sigma - Aldrich 
7.  Didodecyldimethylammonium 
bromide (DMAB) 98.0% 
Sigma - Aldrich 
8.  HPLC-grade absolute 
ethanol 
Fisher-Scientific 
9.  Purified water Elga 
10.  Y- Shaped microchannel 
reactor 
Epigem 
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2.1.2 Production of hydrocortisone and prednisolone 
nanosuspensions  
2.1.2.1 Production of uncoated nanoparticles 
In this project, the production of hydrocortisone and prednisolone 
nanosuspensions was undertaken using the bottom-up solvent - anti solvent 
precipitation method. Preparation of hydrocortisone nanoparticles was 
undertaken using the method described by Ali et al. (2009b), with slight 
modification. 
A 1% w/v solution of hydrocortisone or prednisolone in ethanol was combined 
with an anti solvent (aqueous solution of stabilizers) in a Y - micro channel 
reactor (100 inlet angle, internal diameter 0.5 mm).  Precipitation occurred as the 
solute and the aqueous anti-solvent solutions were combined at a pre-controlled 
flow rates using a dual syringe driver pump, model 33 (Harvard Apparatus, 
USA). Drug solution and anti-solvent solution flow rates used to prepare 
hydrocortisone and prednisolone nanosuspensions were 1:3.5 and 1:3.0 
ml/min, respectively.  To achieve suspension stability, the anti-solvent contained 
a combination of steric and electrostatic stabilizers: hydroxypropylmethyl 
cellulose (HPMC, 15 cPs), polyvinylpyrrolidone K30 (PVP) and sodium dodecyl 
sulphate (SDS) at concentrations of 0.2%, 0.2% and 0.05 % w/v, respectively.  
Formed nanosuspensions were then characterized for particle size, size 
distribution and -potential using the Zetasizer Nano, model 3600 (Malvern 
Instruments, UK) at 25oC, without further dilution. Nanoparticles were monitored 
for particle size and -potential over 28 days.  
The selection of ethanol as a solvent for hydrocortisone and prednisolone was 
due to its safety profile among other pharmaceutically – acceptable water-
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miscible candidate solvents (Patravale et al., 2004). It is also well known that 
ethanol is able to solubilise hydrocortisone (14.7 mg/ml) and prednisolone (24 
mg/ml) (Ali et al., 2009b, Ali et al., 2009a).  
The presence of the combination of PVP and HPMC in the stabilizer mixture 
confers optimum stability for formed drug crystals (Ali et al., 2009b). HPMC tend 
to arrest crystal growth due to its surface activity, as it bears hydrophobic 
(methoxyl) and hydrophilic (hydroxypropyl) groups that enable HPMC to adsorb 
to the hydrophobic solid surface of newly precipitated drug and hereby, 
prevents or retards particle growth (Douroumis and Fahr, 2007, Rasenack et al., 
2003, Verma et al., 2009).     
In addition, the obtained physical stability of drug crystals may also be attributed 
to the interaction between the carbonyl group of PVP and functional groups of 
HPMC in aqueous solutions forming a surrounding stable hydrodynamic layer 
(Douroumis and Fahr, 2007, Chan et al., 2003). Moreover, it has been reported 
that crystal growth retardation may be due to the adsorption of HPMC and PVP 
polymers into the growing crystal as hydrogen bonding formed (Taylor and 
Zografi, 1997), as well as by the formation of hydrodynamic boundary layer 
around growing crystals in which polymer molecules accumulate (Raghavan et 
al., 2001, Raghavan et al., 2003) .  
 
2.1.2.2 Surface – modified nanoparticles 
The surface charge of steroid nanoparticles was tuned by the adsorption of 
either a single or dichained quaternary ammonium surfactant. Single-chained, 
cetyltrimethylammonium bromide (CTAB) and di-chained, didodecyldimethyl-
ammonium bromide (DMAB) cationic surfactants were used (Figure 2.1).  
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Figure 2.1 Chemical structures (in two dimensions) of (i) CTAB and (ii) DMAB 
quaternary ammonium cationic surfactants 
 
 
 
 
 
                                                                                                         
 
 
Aqueous solutions of each surfactant at concentrations of 0.01, 0.025, 0.05, 0.1 
and 0.2 % w/v (up to concentration of 0.1% w/v for DMAB) were prepared for 
surface modification of the previously prepared corticosteroid nanoparticles.  
Being an anionic surfactant, SDS was omitted in the preparation of CTAB and 
DMAB - coated nanoparticles to avoid charge counteraction on nanoparticles 
surface (the inclusion of SDS on initial experiments attributed to failure to obtain 
(i) CTAB  
 
 
(ii) DMAB 
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cationic particle surface charge). However, due to the anionic nature of 
unmodified particles, mixing of cationic surfactant solutions with uncoated 
nanoparticle suspensions has the potential for formation of ionic bonds. 
Surface - charge modification of nanoparticles was achieved by adding 1 ml of 
nanosuspension to 25 ml of aqueous solution of one of the two cationic 
surfactants. The mixtures were stirred for 24 hours at room temperature. After 
24 hours, the particle size and -potential of coated particles were measured 
using the Zetasizer Nano (Malvern Instruments, UK) without further dilution. The 
above protocol for coating nanoparticles was adapted from (Peetla and 
Labhasetwar, 2009) with slight modification. Nanosuspensions were then stored 
at room temperature. To test their stability, nanoparticles were monitored on a 
weekly basis by measuring particle size and -potential for 28 days. 
  
2.1.2.2.1 Selection of CTAB and DMAB cationic surfactants   
There are a number of available surface modifying agents (such as lipids, 
poloxamer and surfactants) that are currently used to modify the surface 
properties of particles for different purposes. The aim of this part of the project 
was to manipulate the surface of the previously prepared steroid nanoparticles 
to obtain a positive surface charge. The obtained cationic particles were 
intended for subsequent cell uptake studies using the HaCaT cell line (a 
mammalian keratinocyte cells).  Therefore, careful consideration of the selection 
of the appropriate surface modifiers was essential.  In order to achieve this goal, 
two quaternary ammonium cationic surfactants, namely CTAB and DMAB, were 
selected to be used for adsorption on nanoparticles. Encouraging results have 
previously been reported in literature describing the application of these two 
P a g e 45 Formation and cell interaction of hydrocortisone and prednisolone nanoparticles  
 
surfactants for nanoparticle surface modification (Cui et al., 2003, Al-Thabaiti et 
al., 2008), which included description of their role in enhancing the cellular 
uptake over unmodified nanoparticles (Peetla and Labhasetwar, 2009, 
Labhasetwar et al., 1998, Panyam and Labhasetwar, 2003) 
Moreover, the simple method which was used to produce particles modified with 
these cationic surfactants was also considered to be advantageous. 
Furthermore, the commercial availability of these surfactants produced an 
additional attractiveness over other. All these criteria of CTAB and DMAB 
surfactants have eventually lead to their selection when compared to other 
surface modifying agents. The selection of two surfactants was made for 
comparison purposes, as initial experiments showed a different level of surface 
positive charge (measured as -potential) obtained with each surfactant. 
Surface charge of CTAB-modified steroid particles ranged between +5 and +59 
mV, whereas -potential ranging between +27 and +78 mV was recorded for 
particles coated with DMAB surfactant.  
    
2.1.3 Characterization of nanosuspensions 
2.1.3.1 Particle size measurement 
Particle size and polydispersity index of nanosuspensions were measured using 
dynamic light scattering (DLS) using the Zetasizer Nano, installed with Zetasizer 
software version 6.01 (Malvern Instruments, UK).  Nanosuspension samples 
were measured at 25oC, using Zen0112 low-volume disposable sizing cuvettes 
and selecting water as dispersant (viscosity: 0.8872 cP, refractive index (RI): 
1.330). The mean value of 3 measurements was taken for each sample. 
Samples were measured without further dilution. 
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2.1.3.2. - potential measurement 
Hydrocortisone and prednisolone nanosuspensions were measured for their 
surface charge using Zetasizer Nano, installed with Zetasizer software version 
6.01 (Malvern Instruments, UK). Samples were characterized for -potential 
using Smoluchowski equation model (f(a) value: 1.5), and water as dispersant 
(viscosity: 0.8872 cP, (RI): 1.330, dielectric constant: 78.5). Samples were 
measured without further dilution using DTS1060C clear disposable Zeta cells, 
with automatic measurement duration option (minimum of 10 runs and 
maximum of 100 runs) at 25oC. Average of 3 measurements was recorded for 
each sample.  
 
2.1.3.3. Quantification of nanosuspensions 
Prepared nanosuspensions were quantified spectrophotometrically for their 
drug content.  Samples were adequately diluted with ethanol (50 l sample 
completed to 10 ml with ethanol) and assayed with V-530 UV-Vis 
spectrophotometer (Jasco, Japan) at wavelength of 247 nm for either 
hydrocortisone or prednisolone. Drug concentrations were then obtained in 
reference to hydrocortisone (R2=0.9993) and prednisolone (R2=0.9996) 
calibration curves.  
 
2.1.3.4. Transmission electron microscopy (TEM) 
Nanosuspension samples (10 l) were adsorbed on to the surface of hydrophilic 
200-mesh carbon grids. A small piece of filter paper was then immediately held 
laterally for few seconds to remove excess liquid and leave a thin film of the 
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sample on the grid. This latter step also minimized the risk of particle 
aggregation during sample drying time. Air – dried samples were then examined 
using Tecnai 12 BioTWIN TEM (FEI, Netherlands) at acceleration voltage of 
120kV (unless otherwise stated).  Digital images were taken using an attached 
Mega view III camera. 
 
2.1.3.5. Differential scanning calorimetry (DSC) 
Samples of precipitated and raw hydrocortisone (about 4mg) were run at a 
scanning rate of 10 °C/min under nitrogen atmosphere in a differential scanning 
calorimeter (TA Q2000, USA).  Scan temperature ranged from 20 to 250 °C.  
In order to obtain solid sample of hydrocortisone nanoparticles, 
nanosuspensions were centrifuged at 25000 rpm for 30 min using an Avanti 
ultracentrifuge (Beckmann, USA) operating at 4 °C. Supernatant was discarded 
and the precipitated soft pellet residue was dried in electrical heated vacuum 
desiccators at the temperature of 40 °C and -25 inch Hg vacuum.  
 
2.1.3.6. Powder X-ray diffraction (PXRD) 
Powder X-ray diffraction of dried hydrocortisone nanoparticles samples was 
recorded with a Siemens D5000 diffractometer (Siemens, Germany), using 
Cu Kα radiation (λ = 1.5418 Å). Samples of precipitated and raw hydrocortisone 
were scanned over an angular range of 2 – 50° (2θ), with a step width of 0.05° 
and a count time of 3 seconds per step. Samples were rotated at 30 rpm during 
analyses. The generator was set to voltage of 40 kV and filament emission of 
30 mA. A 5mm diameter by 1mm depth sample holder was used.   
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2.2 Cell – drug interaction (In vitro part) 
2.2.1 Materials 
Materials used in this part of the study are listed in Table 2.2. All chemicals 
employed were as purchased without further purification.   
 
Table 2.2 List of chemicals used in the cell translocation part of the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No Name of chemical Supplier 
1.  Human adult low calcium 
temperature (HaCaT) keratinocytes  
Kindly donated by Dr. 
S. Britland - University 
of Bradford 
2.  Lipopolysaccharides (LPS) from  E.Coli Sigma - Aldrich 
3.  Sodium nitrite (1M)  Sigma - Aldrich 
4.  Griess' reagent for nitrite Sigma - Aldrich 
5.  Hank's balanced salt solution 
(HBSS) 
Sigma - Aldrich 
6.  Roswell Park Memorial Institute 
(RPMI 1640) Culture medium 
Sigma – Aldrich 
7.  Amphotericin (250 g/ml)  Sigma - Aldrich 
8.  Streptomycin/penicillin(10mg/10.000U)/ml) Sigma - Aldrich 
9.  L- glutamine (200 mM) Sigma - Aldrich 
10.  Foetal calf serum (FCS) Promo-Cell GmbH 
11.  Trypsin-EDTA (0.25%) Sigma - Aldrich 
12.  Glutaraldehyde (25%) Sigma - Aldrich 
13.  Formaldehyde (36.5%) Sigma - Aldrich 
14.  Phosphate buffer tablets  Sigma - Aldrich 
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2.2.2 Methods 
2.2.2.1. HaCaT Cell culture 
HaCaT (a human keratinocyte cell line) cells were initially provided as confluent 
cells in RPMI 1640 culture medium in 25 cm2 culture flasks. Cells were split as 
follows: old culture medium was discarded and flasks washed three times with 5 
ml of Hank's balanced salt solution (HBSS). In order to detach cells from the 
surface, 1 ml trypsin solution, a proteolytic enzyme, was added and flasks 
incubated at 37oC for 5 minutes. Cells were checked every 1 minute. This step 
is known as trypsinization. When all cells were detached from the flask's 
surface, trypsin's activity was neutralized by adding 5 ml of culture medium: 
Roswell Park Memorial Institute (RPMI-1640) culture medium with phenol red 
and HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) modification 
and supplemented with 10% foetal calf serum (FCS), L-glutamine (4 mM), 
penicillin (100 IU/ml), streptomycin (100 g/ml) and amphotericin B (0.5 g/ml). 
The cell suspension was then transferred to a sterile 15-ml centrifuge tube and 
centrifuged at 1600 rpm for 5 minutes. The supernatant was discarded and the 
formed cell pellet was resuspended in 6 ml culture medium. Cells were then 
plated by adding 1 ml of cell suspension to 5 ml of fresh culture media in 25 cm2 
culture flasks and incubated at 37oC. 
When cells reached confluence on day 4, cells were split again as above and so 
were maintained throughout the study. 
 
2.2.2.2. Lipopolysaccharide (LPS) stimulation 
In order to test the response of HaCaT cells to LPS treatment, cells were 
treated with LPS, as an inflammatory promoter, to induce nitric oxide (NO) 
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production. The LPS – induced amounts of NO contribute to inflammatory 
conditions (Yu et al., 2009). When cells reached confluence on day 4, the old 
culture medium was washed with HBSS and replaced with serum – free culture 
medium (RPMI 1640 culture media supplemented with 2 mM L-glutamine) and 
incubated at 37oC. After 24 hours, cells were rinsed with HBSS and treated with 
0, 10, 50 and 100 g/ml LPS solutions in serum-free culture medium. After 
another 24 hours, cell supernatants were collected and centrifuged at 1700 rpm 
for 5 minutes. Cell culture supernatants were examined for levels of NO by 
adding 100 l of each supernatant to 100l of Griess' reagent for nitrite (30 % 
acetic acid, 0.15% 2-naphthylamine and 0.15% sulfanilic acid in water) in 96-
well plate and absorbance measured at 570 nm after 10 minutes incubation at 
room temperature. Absorbance was measured using absorbance microplate 
reader ELx 800 (Biotek Instruments, USA) at wavelength of 570 nm. NO 
concentration levels were obtained from sodium nitrite calibration curve at 570 
nm (R2=0.9969). All LPS treatments were conducted in triplicate.  
    
2.2.2.3 The pharmacological effect of steroid nanoparticles on 
nitric oxide (NO) production 
When the cultured cells reached confluence, the old culture medium was 
discarded and flasks were washed twice with HBSS. Cells were then incubated 
for 1 hour at 37oC with one of the treatments of drug nanoparticles (57 or 75 
g/ml) in serum - free culture medium (supplemented with 2 mM glutamine). 
Every set of flasks was assigned for testing the effect of definite drug content. 
With every set of treated flasks, a control flask was incubated containing only 3 
ml serum - free culture medium.  After 1 hour incubation, supernatants were 
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discarded, and flasks washed again twice with HBSS in order to remove any 
drug residuals. 2 ml of 100 g/ml LPS in serum – free medium was added to 
control and treated flasks and the cells were incubated for 24 hours at 37 oC. 
After 24-hours incubation, supernatants were withdrawn from the culture flasks 
and centrifuged at 1700 rpm for 5 minutes. In Costar 96 - well plates, 100 l of 
each supernatant was added to 100 l Griess' reagent, mixed and incubated at 
room temperature for 10 minutes. Afterwards, absorbance was measured using 
absorbance microplate reader ELx 800 (Biotek Instruments, USA) at 
wavelength of 570 nm. NO concentrations were obtained from sodium nitrite 
calibration curve (R2=0.9969) at 570 nm. All cell-nanoparticle treatments were 
conducted in triplicate. 
 
2.2.2.3.1 Quantification of LPS – induced NO production 
NO production was quantified indirectly by measuring nitrite levels (a stable end 
product of NO) in the cell supernatant using diazotization Griess reaction (Nakai 
et al., 2004, D’Agostino et al., 1998, Wolf et al., 2009). The Griess assay is 
based on the chemical reduction of nitrate (metabolite of NO) to nitrite by nitrate 
reductase. Griess assay determines NO levels through a sequence of chemical 
reactions. First, a nitrosating agent - produced by acidified nitrite – reacts with 
sulfanilic acid and produces a diazonium ion. The diazonium ion is then coupled 
to 2-naphthylamine forming a chromophoric derivative, which absorbs light at 
540 – 570 nm (Lobo, 2009). NO concentrations were obtained from sodium 
nitrite calibration curve at 570 nm. 
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2.2.2.4 Electron microscopy for imaging of nanoparticle uptake 
by HaCaT cells  
With the aim of evaluating the cellular uptake of drug nanoparticles, untreated 
(control) and nanoparticle – treated cells were prepared for examination with 
transmission electron microscopy. Treated cells were incubated with 
hydrocortisone nanoparticles (final concentration of 75 g/ml) for one 1 hour, as 
described in Section 2.2.2.3. Cells were then rinsed with warm HBSS to remove 
excess particles and then trypsinized (1ml trypsin) at 37oC for 5 minutes. 
Excess serum-containing RPMI 1640 culture medium (5ml) was added to 
neutralize trypsin action and cell suspensions were then transferred to 
centrifuge tubes and spun at 1600 rpm for 5 minutes.  
Supernatants were discarded and each cell pellet was re-suspended in 3ml of 
RPMI 1640 culture medium. Cells were then fixed (primary fixation) in 6 ml of 
1:1 warm mixture of the fixative solution (a mixture of 2.5% glutaraldehyde and 
4% formaldehyde in phosphate buffer saline (PBS) solution (pH 7.4)) and cell 
suspension for one hour at room temperature. Cells were centrifuged at 800 
rpm for 5 minutes, fixative solution was pipetted off and replaced with fresh 
fixative solution overnight. In the following day, the fixative solution was washed 
off using PBS before post-fixation. Cells were then post-fixed with 1% osmium 
tetroxide (OsO4) solution in PBS for one hour at room temperature. Cells were 
washed twice for 30 minutes in PBS and stored overnight at 4oC before moving 
to the dehydration phase. Dehydration through series of acetone concentrations 
was undertaken (the use of ethanol in this step was avoided to avoid dissolving 
the possibly available drug particles). Cell specimens were passed through 
acetone gradients of 25%, 50%, 70%, 90% and finally twice using 100% 
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acetone, for 20 minutes for each acetone concentration at room temperature. 
Afterwards, 25%, 50% and 75% Spurr's resin (an epoxy resin) were used as 
embedding media for 30 minutes each, followed by double treatments with 
100% Spurr resin (all at room temperature). The resultant blocks were 
polymerized overnight at 70oC. Samples were then sectioned at around 80 nm, 
stained with saturated uranyl acetate in 50% ethanol then Reynolds lead citrate 
solution, 15 minutes each. All cells were viewed with Tecnai 12 BioTWIN TEM 
(FEI, Netherlands). The preparation steps from cells post-fixation to imaging 
phase were undertaken at the Technology Facility/Biology Department - 
University of York.    
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CHAPTER III 
 
RESULTS AND DISCUSSION 
 
(PREPARATION OF STEROID  
DRUG NANOPARTICLES) 
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3.1 Workflow of the current chapter 
This chapter covers the results and discussion of nanoparticle preparation and 
characterization experiments described in Chapter 2 (Sections 2.1.2.1. and 
2.1.2.2.). There are separate results and discussion for hydrocortisone and 
prednisolone nanoparticles. For each drug nanoparticle formulation, the results 
and discussion for uncoated nanoparticles are reviewed first, followed by those 
of coated nanoparticles; surface - modified nanoparticles with cationic 
surfactants. The term "uncoated nanoparticles" used throughout this study is 
used to describe nanoparticles produced using the methods in Section 2.1.2.1., 
where the combination of steric (HPMC and PVP) and electrostatic (SDS) 
stabilizers was used to prepare the precipitated nanoparticles. "Coated 
nanoparticles" refers to the drug nanoparticles prepared by adsorbing a 
selected cationic surfactant on to the previously –uncoated drug nanoparticles 
(stabilized with HPMC and PVP), as described in Section 2.1.2.2. 
    
3.2 Hydrocortisone nanoparticles 
This section presents the studies undertaken using hydrocortisone 
nanoparticles. Particle size distribution and surface charge were examined for 
the formulations described in this study. Results generated for the uncoated and 
coated hydrocortisone nanoparticles are described in Sections 3.2.1 and 3.2.2, 
respectively.  
3.2.1 Uncoated hydrocortisone nanoparticles 
Nanosuspensions of uncoated hydrocortisone nanoparticles were prepared as 
described in Section 2.1.2.1. Results for particle size, polydispersity index and 
-potential of suspensions (1.9 mg/ml±0.15) were determined after seven days 
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periods up to 21 days. The results are summarized in Table 3.1. All 
measurements were conducted in triplicates, and reported as mean± standard 
error of mean (SE). 
 
Table 3.1 Particle size and -potential of uncoated hydrocortisone nanoparticles 
over 21 days (Mean ± standard error of mean) 
 
 
 Days 
 
0 7 14 21 
 
Particle size in 
nm (PDI) 
 
466.0 ± 16.5 
(0.17 ± 0.01) 
 
451.4 ± 12.8 
(0.14 ± 0.01) 
 
468.3 ± 12.6 
(0.11 ± 0.02) 
 
446.0 ± 6.3 
(0.15± 0.005) 
 
 - potential 
(- mV) 
 
 
 
1.59 ± 0.3 
 
 
1.46 ± 0.04 
 
 
1.62 ± 0.2 
 
 
2.06 ± 0.4 
  
 
On day 0 (immediately after 24 hrs stirring) average particle size was 466.0 nm 
± 16.5 (PDI= 0.17). After 7 days, particle size was reduced slightly to 451.4 nm 
± 12.8 (PDI=0.14). After 21 days, particle size was measured as 446.0 nm ± 6.3 
(PDI=0.15). As shown in Table 3.1, there was no marked growth in particle size 
over 21 days with a fairly narrow size distribution (PDI values between 0.11 and 
0.17) maintained throughout the storage period.  
The  -potential of hydrocortisone  nanoparticles was found to be -1.59 mV ± 0.3 
on day 0.  It did not vary greatly over the first 14 days (-1.62 ± 0.2mV on day 
14), a slight increase was however observed in the surface charge on day 21 
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with -potential of -2.06 mV ± 0.4 (-potential measurements are shown on the 
secondary vertical axis on Figure 3.1).  
The particle surface negative charge is probably due to the anionic nature of 
sodium lauryl sulphate (SDS) (Cui and Mumper, 2002). However, the recorded 
low -potential may reflect the effect of increased thickness of the diffuse double 
layer due to the adsorbed steric stabilizers (PVP and HPMC) on particles 
surface (Verma et al., 2009). Thereby, the measured -potential is the result of 
the particle surface properties and the interaction of the particle surface with the 
used combination of stabilizers.  
 
    
Figure 3.1 Particle size (primary vertical axis) and -potential (secondary 
vertical axis) of uncoated hydrocortisone nanoparticles over 21 days (Mean ± 
standard error of mean) 
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Transmission electron microscopy (TEM): 
A sample of hydrocortisone nanosuspension (particle size=466.0 nm, PDI=0.19) 
was prepared for TEM as described in Section 2.1.3.4. Micrograph of TEM 
imaging of hydrocortisone nanoparticles is shown in Figure 3.2. The 
polydispersed hydrocortisone nanoparticles showed on Figure 3.2 posses a 
spherical morphology with evidence of an agglomerated surface layer. TEM 
image support the average particle size obtained by DLS (466.0 nm). The 
shape of particles in Figure 3.2 looked similar to the precipitated hydrocortisone 
particles imaged and reported by Ali et al. (2009b).   
 
 
Figure 3.2 TEM image of hydrocortisone nanoparticles (Scale bar =2m) 
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Figure 3.3 Powder X-ray diffraction (PXRD) pattern of hydrocortisone 
 
 
 
Comparison of supplied hydrocortisone and that produced by the precipitation 
process clearly points to the polycrystalline or amorphous nature of the material. 
As typified by a broad peak with some evidence of diffraction buried within the 
noise of the signal.  
 
Figure 3.4 Differential scanning calorimetry (DSC) result of processed and 
unprocessed hydrocortisone 
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The DSC clearly corroborates the picture of polycrystalline or amorphous nature 
of the material obtained from the PXRD results, with a broad appearance in the 
scan from 55 to 100 oC (Figure 3.4). 
 
3.2.2 Coated hydrocortisone nanoparticles 
Hydrocortisone nanoparticles modified with one cationic surfactant were 
prepared as described in Section 2.1.2.2. The employed uncoated 
nanosuspensions (2.1 mg/ml ± 0.03) were stabilized with a combination of steric 
stabilizers (HPMC and PVP) as explained in Section 2.1.2.2. Results generated 
for drug particles coated with CTAB and DMAB are presented in Sections 
3.2.2.1 and 3.2.2.2, respectively.   
  
3.2.2.1 CTAB - coated hydrocortisone nanoparticles 
CTAB – coated nanoparticles, with five different CTAB concentrations in the 
range 0.01 – 0.2% w/v, were prepared as described in Section 2.1.2.2 and 
characterized for their particle size distribution and -potential at seven days 
periods up to 28 days. Table 3.2 shows the measurements of particle size and 
-potential for the 0.2% w/v CTAB – coated nanoparticles. The results shown 
are the average of triplicate measurements ± standard error of mean (SE). 
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Table 3.2 Particle size and -potential of 0.2% CTAB - coated hydrocortisone 
nanoparticles over 28 days (Mean ± standard error of mean) 
  
 0.2 % w/v CTAB 
 
Days 
 
Particle size in nm±SE 
(PDI±SE) 
 
-potential (+mV) 
±SE 
 
 
0 
 
178.4 ± 20.5 
 
(0.26 ±0.04) 
 
52.0 ± 1.7 
 
 
7 
 
192.5 ±16.8 
 
(0.28 ±0.03) 
 
 
47.7 ± 1.7 
 
 
14 
 
192.7 ±31.1 
 
(0.37 ±0.06) 
 
 
 
50.3  ± 3.9 
 
 
 
21 
 
186.5 ±31.1 
 
(0.37 ±0.03) 
 
 
48.2 ± 2.7 
 
 
 
28 
 
195.4 ±33.3 
 
(0.34 ±0.03) 
 
 
46.3 ± 2.1 
 
 
 
 
Particle size of 0.2% w/v CTAB - coated hydrocortisone nanoparticles was 
178.4 nm ± 20.5 on day 0. Particle size increased slightly on day 7 to 192.5 nm 
±16.8 and remained almost the same without substantial change to reach 195.4 
nm ± 33.3 on day 28. -Potential values decreased slightly from +52.0 mV ± 1.7 
on day 0 to +46.3 mV ± 2.1 on day 28 (Table 3.2).  
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Table 3.3 Particle size and -potential of 0.1 and 0.05% CTAB - coated 
hydrocortisone nanoparticles over 28 days (Mean ± standard error of mean) 
 
 0.1% w/v CTAB 0.05% w/v CTAB 
Days Particle size, 
nm±SE 
(PDI±SE) 
-potential 
(+mV) 
±SE 
Particle size, 
nm±SE 
(PDI±SE) 
-potential 
(+mV) 
±SE 
 
0 
 
200.3±19.7 
 
(0.27±0.03) 
 
 
45.9±2.1 
 
164.6±17.4 
 
(0.31±0.02) 
 
36.1±1.7 
 
7 
 
179.6± 26.3 
 
(0.31±0.04) 
 
 
44.7 ±1.3 
 
 
147.2±12.2 
 
(0.32±0.03) 
  
 
31.5±0.7 
 
14 
 
163.9±28.6 
 
(0.27±0.03) 
 
 
 
44.5±3.0 
 
149.4±4.6 
 
(0.32±0.05) 
 
 
 
30.3±1.4 
 
 
21 
203.5±28.3 
 
(0.30±0.01) 
 
42.3±2.3 
180.3±7.7 
 
(0.32±0.03) 
 
29.0±2.0 
 
 
28 
187.7±26.0 
 
(0.30±0.04) 
 
40.9±2.7 
 
153.0±13.8 
 
(0.32±0.04) 
 
28.1±0.5 
 
 
Particle size of hydrocortisone nanoparticles coated with 0.1% w/v CTAB 
showed small decrease from 200.3 nm ±19.7 to 163.9 nm ±28.6 in the first 14 
days, before increasing again to 203.5 nm ±28.3, with final slight drop to 187.7 
nm ±26 on day 28. Figure 3.5 demonstrates how both 0.05 and 0.1% w/v CTAB 
– coated nanoparticles showed the same pattern over 28 days (Table 3.3 and 
Figure 3.5).  
 As for particles coated with  0.2% w/v CTAB, the -potential of 0.1% w/v CTAB 
- coated nanoparticles showed a similar pattern, with surface charge decreasing 
slightly from +45.9 mV ±2.1 on day 0 to +40.9 mV ±2.7 on day 28 (approximate 
+5mV drop) (Figure 3.7) .  
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Figure 3.5 Particle size of 0.05 and 0.1% w/v CTAB-coated nanoparticles 
(mean± standard error of mean) 
 
 
 
  
 
The summary of particle size and -potential measurements for 0.01 and 
0.025% w/v CTAB – coated nanoparticles is shown on Table 3.4. -potential for 
particles coated with 0.025 % CTAB ranged between +14.3 mV ±1.1 and +16.0 
mV ±0.69. For particles coated with 0.01 % CTAB, measured -potential ranged 
between +5.6 mV ±0.54 and +7.0 mV ±0.59. Effectively, no overall changes can 
be seen in particle size measurements for both types of coated particles (Figure 
3.6). In accordance with Tables 3.2 and 3.3, it appeared that -potential values 
were proportional to CTAB concentration. 
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Table 3.4 Particle size and -potential of 0.025 and 0.01% w/v CTAB - coated 
hydrocortisone nanoparticles over 28 days (Mean ± standard error of mean): 
 
 
Figure 3.6 Particle size of 0.01 and 0.025% CTAB-coated nanoparticles (Mean 
± standard error of mean): 
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 0.025 % w/v CTAB 0.01% w/v CTAB 
Days Particle size, 
nm±SE 
(PDI±SE) 
-potential 
(+mV) 
±SE 
Particle size, 
nm±SE 
(PDI±SE) 
-potential 
(+mV) 
±SE 
 
0 
 
169.5±16.5 
 
(0.27±0.01) 
 
14.3±1.1 
 
190.8±5.3 
 
(0.22±0.02) 
 
6.03±0.57 
 
 
 
7 
 
168.5±11.7 
 
(0.27±0.02) 
 
14.7 ±0.75 
 
 
205.7±11.8 
 
(0.24±0.02) 
 
5.6 ±0.54 
 
 
14 
187.7±4.9 
 
(0.21±0.02) 
 
 
15.2±1.41 
 
 
208.5±5.7 
 
(0.23±0.03) 
 
 
6.26±0.44 
 
 
 
21 
182.3±12.0 
 
(0.24±0.01) 
 
14.7±0.14 
 
 
196.9±10.6 
 
(0.18±0.02) 
 
6.92±0.91 
 
 
 
28 
155.8±3.9 
 
(0.22±0.04) 
 
16.0±0.69 
 
 
203.6±10.1 
 
(0.22±0.02) 
 
7.0±0.59 
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Table 3.5 and Figure 3.7 summarize the -potential values for all CTAB – 
coated nanoparticles, and show a direct relationship between cationic surfactant 
concentration and the measured positive surface charge. The surface charge 
measured with individual surfactant concentration has changed marginally 
(approximately ±1 – 8 mV) throughout 28 days period. Therefore, application of 
different amounts of CTAB provides a means by which the surface charge of 
hydrocortisone nanoparticles can be manipulated. 
 
Table 3.5 Summary of  -potential measurements of CTAB - coated 
hydrocortisone nanoparticles (Mean ± standard error of mean) 
 
 
 
CTAB concentration (% w/v) 
Days 0.01 0.025 0.05 0.1 0.2 
 
0 
 
 
6.0±0.57 
 
 
14.3±1.1 
 
36.1±1.7 
 
 
 
45.9±2.1 
 
 
52.0 ± 1.7 
 
7 
 
 
5.6 ±0.54 
 
14.7 ±0.75 
 
 
31.5±0.7 
 
 
44.7 ±1.3 
 
 
 
47.7 ± 1.7 
 
14 
 
 
6.3±0.44 
 
 
 
 
15.2±1.41 
 
 
30.3±1.4 
 
 
44.5±3.0 
 
 
50.3  ± 3.9 
 
21 
 
 
6.9±0.91 
 
 
 
 
14.7±0.14 
 
 
 
 
29.0±2.0 
 
 
 
42.3±2.3 
 
 
48.2 ± 2.7 
 
28 
 
 
7.0±0.59 
 
 
 
 
16.0±0.69 
 
 
28.1±0.5 
 
 
 
40.9±2.7 
 
 
 
46.3 ± 2.1 
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Figure 3.7 - potential of CTAB - coated hydrocortisone nanoparticles over 28 
days (Mean ± standard error of mean) 
 
 
 
 
 
Initially, a relatively sharp rise in particle surface charge is observed up to 
0.1%w/v surfactant concentration. Up to this point, -potential is accordingly 
doubled for a two-fold increase in surfactant concentration: from +6.26 to +15.2 
then +30.3 mV at 0.01, 0.025 and 0.05% w/v, respectively (Table 3.5 and 
Figures 3.7, 3.8). A less sharp rise is then observed, with a 47% and 13% 
increase in -potential for increases in surfactant concentration from 0.05 to 
0.1% and from 0.1 to 0.2% w/v, respectively. The plateau effect observed in 
Figure 3.8 may be attributed to the "saturable nature" of particle surfaces with 
the surfactant coating. Therefore, surface charge increases become less 
appreciable as the surfactant concentration increases above 0.1% w/v, giving a 
plateau effect (Figure 3.8).  
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Figure 3.8 Relationship between CTAB concentration and the particle surface 
charge of hydrocortisone nanoparticles determined on day 14 (Mean ± standard 
error of mean) 
 
 
  
 
 
3.2.2.2 DMAB - coated hydrocortisone nanoparticles 
DMAB – coated nanoparticles were prepared (as described in Section 2.1.2.2) 
using aqueous surfactant solutions in the concentration range of 0.01 – 0.1% 
w/v DMAB. Nanoparticles were monitored for particle size distribution and -
potential over 7 days periods up to 28 days. Table 3.6 shows the 
measurements of particle size and -potential for 0.1 and 0.05 % w/v DMAB – 
coated nanoparticles. The results are the average of triplicate measurements ± 
standard error (SE). 
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Table 3.6 Particle size and -potential for 0.1 and 0.05 % w/v DMAB – coated 
hydrocortisone nanoparticles over 28 days (Mean ± standard error of mean) 
 
 0.1% w/v DMAB 0.05% w/v DMAB 
 
Days 
Particle size, 
nm±SE 
(PDI±SE) 
-potential 
(+mV) 
±SE 
Particle size, 
nm±SE 
(PDI±SE) 
-potential 
(+mV) 
±SE 
 
0 
361.4±38.8 
 
 (0.66±0.07) 
 
75.9±2.0 
212.3±25.5 
 
 (0.42±0.06) 
 
 
66.1±1.2 
 
 
7 
395.0±68.1 
 
(0.62±0.06) 
 
 
77.0±2.9 
198.5±22.1 
 
(0.40±0.05) 
 
67.5±0.58 
 
 
14 
395.9±29.8 
 
(0.66±0.03) 
 
 
75.6±3.0 
240.5±28.3 
 
(0.45±0.03) 
 
 
64.9±1.7 
 
 
21 
365.7±26.7 
 
(0.65±0.05) 
 
  
72.7±1.9 
 
288.8±45.4 
 
(0.50±0.05) 
 
 
67.2±2.5 
 
 
28 
423.8±45.4 
 
(0.55±0.02) 
 
74.6±2.0 
328.4±64.6 
 
(0.49±0.02) 
 
 
63.6±1.1 
 
 
The size of nanoparticles coated with 0.1 % DMAB increased gradually over 28 
days from 361.4 nm ±38.8 on day 0 to 423.8 nm ±45.4, which indicates particle 
growth.  -potential however ranged from +72.7 mV ±1.9.0 to +77.0 mV ±2.9 
throughout the whole period with no appreciable change during storage (Table 
3.6 and Figure 3.9). Particle size of 0.05% DMAB nanoparticles increased from 
212.3 nm ±25.5 on day 0 to 328.4 nm ±64.6 on day 28, with -potential ranging 
from +63.6 mV ±1.1 to +67.5 mV ±0.58 (Table 3.6 and Figure 3.9). 
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Figure 3.9 Particle size of 0.05 and 0.1% DMAB-coated hydrocortisone 
nanoparticles (Mean ± standard error of mean) 
 
 
 
 
 
It was noted that particle size of DMAB – coated nanoparticles are higher than 
that of CTAB – coated nanoparticles. Also PDI values of DMAB – coated 
nanoparticles were relatively high and decreased with lower DMAB 
concentrations.  
The particle size distribution and -potential of the 0.01 and 0.025% w/v DMAB 
– coated nanoparticles are shown in Table 3.7 and Figures 3.10 and 3.11. The 
results show notable increases in particle size from 148.8 nm ±13.9 to 198.3nm 
±28.3 for 0.025% DMAB-coated particles, and from 160.5nm ±  6.4 to ± 179.2 ± 
14.4 for 0.01% DMAB-coated particles over 28 days. -potential however 
appeared to be fairly stable with small decrease observed over 28 days. 
-potential measurements for hydrocortisone nanoparticles coated with different 
concentrations of DMAB are summarized in Table 3.8 and Figure 3.11.  
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Table 3.7 Particle size and -potential of 0.025 and 0.01% w/v DMAB – coated 
hydrocortisone nanoparticles over 28 days (Mean ± standard error of mean) 
 
 0.025% w/v DMAB 0.01% w/v DMAB 
 
Days 
Particle size, 
nm±SE 
(PDI±SE) 
-potential 
(+mV) 
±SE 
Particle size, 
nm±SE 
(PDI±SE) 
-potential 
(+mV) 
±SE 
 
0 
 
148.8±13.9 
(0.28±0.02) 
 
44.5±3.6 
 
160.5±6.4 
 (0.22±0.02) 
 
 
30.2±1.6 
 
7 
162.8±9.6 
 
(0.30±0.04) 
 
 
36.3±2.9 
179.3±2.9 
 
(0.28±0.04) 
 
29.4±1.6 
 
 
14 
189.2±19.0 
 
(0.32±0.02) 
 
 
38.3±0.52 
 
197.5±13.0 
 
(0.30±0.03) 
 
27.9±1.7 
 
 
21 
175.9±16.1 
 
(0.27±0.02) 
 
42.8±2.7 
 
 
224.2±13.9 
 
(0.29±0.04) 
 
29.5±1.8 
 
 
28 
198.3±28.3 
 
(0.25±0.05) 
 
41.8±3.8 
179.2±14.4 
 
(0.28±0.04) 
 
27.7±0.24 
 
 
Figure 3.10 Particle size of 0.01 and 0.025% DMAB - coated hydrocortisone 
nanoparticles (Mean ± standard error of mean) 
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Table 3.8 Summary of  -potential measurements of DMAB - coated 
hydrocortisone nanoparticles (Mean ± standard error of mean) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11 - potential of DMAB - coated hydrocortisone nanoparticles over 28 
days (Mean ± standard error of mean) 
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DMAB concentration (% w/v) 
Days 
0.01 0.025 0.05 0.1 
0 30.2±1.6 44.5±3.6 66.1±1.2 75.9±2.0 
7 29.4±1.6 36.3±2.9 67.5±0.58 77.0±2.9 
14 27.9±1.7 38.3±0.52 64.9±1.7 75.6±3.0 
21 29.5±1.8 42.8±2.7 67.2±2.5 72.7±1.9 
28 27.7±0.24 41.8±3.8 63.6±1.1 74.6±2.0 
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As with CTAB – coated nanoparticles, the relationship between the 
concentration of cationic surfactant used and the particle -potential was also 
observed for DMAB – coated nanoparticles. Particle surface charge increases 
exponentially from +27.9 to +75.6 mV in accordance with the DMAB 
concentration (Figure 3.12). Comparing both coated hydrocortisone particles, 
surface charge appears to be more sensitive to DMAB concentrations, as -
potential values were almost double those measured with CTAB – coated 
nanoparticles when comparing equal concentrations of both surfactants (Figure 
3.13).   
 
Figure 3.12 Relationship between DMAB concentration and the particle surface 
charge of hydrocortisone nanoparticles determined on day 14 (Mean ± standard 
error of mean) 
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Figure 3.13 Relationship between cationic surfactant concentration and the 
measured particle surface charge. Results are of hydrocortisone nanoparticles 
determined on day 14 (Mean ± standard error of mean) 
 
 
 
 
Figure 3.14 TEM image of two 0.025% DMAB – coated hydrocortisone 
nanoparticles at 43kV (Scale bar = 500nm) 
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Figure 3.15: TEM image of a single 0.025% DMAB – coated hydrocortisone 
nanoparticle at 87kV (Scale bar = 200nm) 
 
 
 
 
 
Overall, the DMAB- coated hydrocortisone nanoparticles appear to have an 
inner particle as core and outer layer. The morphology of particles is spherical 
with a diameter of approximately 142.5 nm core and 86.1 nm outer layer. This 
support the size measurement results obtained with DLS (particle size 
=138.8nm, PDI = 0.257). 
 
3.3. PREDNISOLONE NANOPARTICLES 
3.3.1. UNCOATED PREDNISOLONE NANOPARTICLES 
Nanosuspensions of uncoated prednisolone nanoparticles were prepared as 
described in Section 2.1.2.1. Stability issues were encountered on preparing 
uncoated prednisolone nanosuspension, as particles showed a tendency to 
grow substantially the following day. However, prednisolone nanosuspensions 
showed an ideal average size distribution monomodal curve (Figure 3.16) when 
samples were measured after preparation, with average PDI of 0.16. 
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Measurements of particle size, polydispersity, -potential (Table 3.9) and TEM 
(Figure 3.17) of freshly - prepared nanoparticles (2.34 mg/ml ± 0.06) were 
undertaken. Similar to hydrocortisone nanoparticles reported in Section 3.1, the 
term "uncoated nanoparticles" indicates the precipitation of prednisolone 
nanoparticles solely with the aid of stabilizers (HPMC, PVP and SDS). 
Unfortunately, no DSC or PXRD was carried out for prednisolone nanoparticles 
owing to the time limit faced at the end of this project. 
 
 
Table 3.9 Particle size and -potential of uncoated prednisolone nanoparticles 
(Mean ±SE of mean) 
 
 
Particle size, nm±SE 
(PDI±SE) 
-potential (-mV) 
±SE 
 
419.9 ± 13.6 
(0.16 ± 0.01) 
 
2.55 ± 0.09 
 
Figure 3.16 Size distribution of a freshly prepared uncoated prednisolone 
nanosuspension (particle size 443.6nm, PDI 0.134) 
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Transmission electron microscopy (TEM) 
A sample of prednisolone nanosuspension (particle size = 361.9 nm, PDI = 
0.153) was prepared for TEM as described in Section 2.1.3.4. TEM image was 
taken of a freshly prepared prednisolone nanosuspension.  
 
 
 
Figure (3.17) TEM micrograph of uncoated prednisolone nanoparticles (Scale 
bar = 500nm) 
 
 
 
 
 
3.3.2 Coated prednisolone nanoparticles 
Prednisolone nanoparticles modified with one cationic surfactant were prepared 
as described in Section 2.1.2.2. The uncoated nanosuspensions (2.28 mg/ml ± 
0.07) used to prepare coated particles were stabilized with a combination of 
steric stabilizers (HPMC and PVP) as explained in Section 2.1.2.2. Results 
generated for prednisolone particles modified with CTAB (Section 3.3.2.1) and 
DMAB (3.3.2.2) are presented. 
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3.3.2.1 CTAB - coated prednisolone nanoparticles 
0.01 – 0.2% w/v CTAB – coated prednisolone nanoparticles were prepared as 
described in Section 2.1.2.2. Particles were characterized for particle size 
distribution and -potential every 7 days up to 28 days. Table 3.10 shows the 
measurements of particle size and -potential for 0.2% CTAB coated 
prednisolone nanoparticles. The results are the average of triplicate 
measurements ± standard error of mean (SE). 
 
Table 3.10 Particle size and -potential of 0.2 %w/v CTAB – coated 
prednisolone nanoparticles over 28 days (Mean ± standard error of mean) 
 
 
 0.2 % w/v CTAB 
 
Days 
 
Particle size, nm±SE 
(PDI±SE) 
 
-potential (+mV) 
±SE 
 
0 
 
155.9±2.4  
 
(0.19±0.003) 
 
59.6±3.3 
 
7 
 
169.4±3.2 
 
(0.23±0.003) 
  
 
54.0±5.6 
 
 
14 
 
166.8±0.6 
 
(0.2±0.007) 
 
 
 
49.3±0.4 
 
 
21 
162.1±5.2 
 
(0.3±0.02) 
 
53.6±4.0 
 
 
28 
154.9±13.7 
 
(0.3±0.04) 
 
53.0±5.6 
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Prednisolone nanoparticles coated with 0.2% CTAB showed a stable size 
profile, where the measured particle size was 155.9nm ±2.9 on day 0, and 
154.9nm±13.7 on day 28. PDI values indicated a good particle size distribution 
over the first two weeks (0.19 - 0.23). However, PDI reached value of 0.3 on 
days 21 and 28; this most likely indicates Ostwald ripening leading to broader 
particle size distribution.  -potential of 0.2% CTAB-coated nanoparticles ranged 
between + 49.3mV ±0.4 and +59.6 mV ±3.3. 
 
Table 3.11 Particle size and -potential of 0.1, 0.05 %w/v CTAB - coated 
prednisolone nanoparticles over 28 days (Mean ± standard error of mean) 
 
 
 0.1% w/v CTAB 0.05% w/v CTAB 
Days Particle size, 
nm±SE 
(PDI±SE) 
-potential 
(+mV) 
±SE 
Particle size, 
nm±SE 
(PDI±SE) 
-potential 
(+mV) 
±SE 
 
0 
 
164.1± 5.1 
 
(0.2±0.02) 
 
40.9±0.3 
 
172.9±7.0 
 
(0.19±0.005) 
 
30.7±0.9 
 
 
7 
 
166.9±6.9 
 
(0.22±0.02) 
 
36.7±1.4 
 
 
186.2±15.5 
 
(0.22±0.009) 
 
29.0±1.8 
 
 
14 
166.1±4.5 
 
(0.22±0.02) 
 
36.0±0.8 
167.2±6.9 
 
(0.18±0.005) 
 
28.3±0.9 
 
 
21 
167.8±4.3 
 
(0.22±0.01) 
 
37.2±1.2 
 
193.8±19.2 
 
(0.18±0.02) 
 
26.9±1.4 
 
28 
187.9±19.7 
 
(0.25±0.03) 
 
36.2±0.8 
 
183.1±18.6 
 
(0.24±0.04) 
 
27.3±1.7 
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Particle size of 0.1% w/v CTAB - coated nanoparticles was within a fairly narrow 
range (164.1 – 187.9nm) over 28 days, with overall PDI values up to 0.25 
(Table 3.11 and Figure 3.18).  -potential values of 0.1% w/v CTAB - coated 
nanoparticles were +40.9 mV ± 0.3 on day 0 and then decreased slightly to 
reach 36.2 mV ±0.8 on day 28.  As expected, -potential values for 0.05% w/v 
CTAB - coated nanoparticles were lower than those of 0.1% CTAB, and were 
ranging between +26.9 mV ±1.4 to +30.7 mV ± 0.9 (Figure 3.18). 
 
Figure 3.18 Particle size of CTAB - coated prednisolone nanoparticles over 28 
days (Mean ± standard error of mean) 
 
 
 
 
Table 3.12 and Figure 3.19 show the particle size distribution for 0.01 and 
0.025% w/v CTAB – coated nanoparticles. Particle size of both coated 
nanoparticles was similar and in the range: 226.6 nm ± 6.5 to 271.4 nm ±6.9 
(0.01% w/v coated particles), and 207.9 nm ± 7.9 to 235.6 nm ±2.0 (0.025% w/v 
–coated nanoparticles). -potential measurements for 0.01% w/v CTAB – 
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coated nanoparticles were +16.4 mV ± 2.2 at day 0 and increased slightly to 
18.1 mV ±1.1on day 28.  -potential values for 0.025% w/v CTAB – coated 
nanoparticles were +7.1 mV ±0.3 on day 0, and remained almost stable before 
reaching potential of +8.4 mV ±1.2 on day 21. A further unexpected increase to 
+11.0 mV ±1.5 was observed on day 28.  
 
 
Table 3.12 Particle size and -potential of 0.025, 0.01 %w/v CTAB - coated 
prednisolone nanoparticles over 28 days (Mean ± standard error of mean) 
 
 
 
 
 
 
 
 
 
  
0.025% w/v CTAB 
 
0.01%  w/v CTAB 
Days Particle size, 
nm±SE 
(PDI±SE) 
-potential 
(+mV) 
±SE 
Particle size, 
nm±SE 
(PDI±SE) 
-potential 
(+mV) 
±SE 
 
0 
 
209.5± 12.6 
 
(0.26±0.05) 
 
16.4±2.2 
 
231.6±6.6  
 
(0.16±0.01) 
 
7.1±0.3 
 
 
7 
 
207.9±7.9 
 
(0.29±0.04) 
  
16.8±0.5 
 
235.4±7.7 
 
(0.21±0.01) 
 
7.9±0.3 
 
14 
 
227.7±23.3 
 
(0.25±0.03) 
 
 
 
17.9±1.2 
226.6±6.5 
 
(0.17±0.01) 
 
 
 
7.9±0.8 
 
21 
235.6±2.0 
 
(0.28±0.04) 
 
18.1±0.6 
 
243.2±1.5 
 
(0.20±0.03) 
 
8.4±1.2 
 
28 
 
210.1±2.9 
 
(0.26±0.05) 
 
18.1±1.1 
271.4±6.9 
 
(0.19±0.01) 
 
11.0±1.5 
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Figure 3.19 Particle size of CTAB - coated prednisolone nanoparticles over 28 
days (Mean ± standard error of mean) 
 
 
 
 
The data showed that increases in CTAB concentrations resulted in the 
formation of prednisolone nanoparticles with increased positive surface charge 
(Table 3.13 and Figures 3.20, 3.21).  
 
Figure 3.20 -potential of CTAB - coated prednisolone nanoparticles over 28 
days (Mean ± standard error of mean) 
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Table 3.13 Summary of  -potential measurements of CTAB - coated 
prednisolone nanoparticles (Mean ± standard error of mean) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CTAB concentration (% w/v) 
Days 
0.01 0.025 0.05 0.1 
0.2 
0 7.1±0.3 16.4±2.2 30.7±0.9 40.9±0.3 59.6±3.3 
7 7.9±0.3 16.8±0.5 29.0±1.8 
 
36.7±1.4 
 
 
54.0±5.6 
 
14 7.9±0.8 17.9±1.2 28.3±0.9 36.0±0.8 
 
 
49.3±0.4 
 
21 8.4±1.2 18.1±0.6 26.9±1.4 37.2±1.2 53.6±4.0 
28 11.0±1.5 18.1±1.1 27.3±1.7 36.2±0.8 53.0±5.6 
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Figure 3.21 Relationship between CTAB concentration and the particle surface 
charge of prednisolone particles, as measured on day 14 (Mean ± standard 
error of mean) 
 
 
 
 
 
3.3.2.2 DMAB - coated prednisolone nanoparticles 
Prednisolone nanoparticles modified with 0.01 – 0.1% w/v DMAB nanoparticles 
were prepared (Section 2.1.2.2) and characterized for particle size distribution 
(polydispersity index) and -potential every 7 days up to 28 days. Table 3.14 
presents the measurements of particle size and -potential for 0.1 and 0.05 % 
w/v DMAB - coated prednisolone nanoparticles. All results are the average of 
triplicate measurements± standard error of mean (SE). 
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Table 3.14 Particle size and -potential for 0.1 and 0.05 %w/v DMAB - coated 
prednisolone nanoparticles over 28 days (Mean ± standard error of mean) 
 
 0.1% w/v DMAB 0.05% w/v DMAB 
Days Particle size, 
nm±SE 
(PDI±SE) 
-potential 
(+mV) 
±SE 
Particle size, 
nm±SE 
(PDI±SE) 
-potential 
(+mV) 
±SE 
0 
 
373.2± 6.8 
 
(0.50±0.02) 
 
78.9±1.6 
 
200.9±15.6 
  
(0.36±0.06) 
 
69.4±3.5 
 
7 
 
377.6±32.9 
 
(0.63±0.002) 
  
 
76.4±0.4 
 
216.2±26.9 
 
(0.43±0.04) 
  
 
68.9±2.8 
 
14 
381.8±18.6 
 
(0.54±0.14) 
 
 
 
75.2±1.2 
204.6±5.1 
 
(0.40±0.01) 
 
 
 
72.5±3.1 
 
21 
389.6±54.9 
 
(0.52±0.13) 
 
 
75.9±2.6 
210.9±5.9 
 
(0.41±0.05) 
 
 
68.6±1.1 
 
28 
382.6±24.9 
 
(0.68±0.08) 
 
75.1±0.7 
233.0±8.8 
 
(0.43±0.02) 
 
69.4±0.5 
 
 
Particle size for 0.1% w/v DMAB – coated nanoparticles was 373.2nm ± 6.8 
upon first measurement, and increased to 382.6nm ±  24.9 on day 28, reaching 
a plateau at day 14 (Figure 3.22). Whereas, particle size of 0.05% DMAB – 
coated particles was nearly half that measured with 0.1% CTAB, ranging from 
200.9nm ±15.6 (day 0) to 233.0nm±8.8 (day 28). 
Measurement of  -potential for both nanoparticles revealed a slight decrease 
over 28 days for 0.1% w/v-coated particles, but negligible change for particles 
coated with 0.05%w/v DMAB (Table 3.14 and Figure 3.24). 
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Figure 3.22 Particle size of DMAB - coated prednisolone nanoparticles over 28 
days (Mean ± standard error of mean) 
 
 
 
 
Particle size measurements for 0.025% DMAB – coated nanoparticles show 
some fluctuation in average particle size. Alternatively, the particle size profile 
for 0.01% DMAB – coated nanoparticles showed greater consistence with a 
relatively slow growth rate as size increased from 203.3 nm  ± 5.7 to 218.5 nm ± 
6.0 over 28 days (Table 3.15 and Figure 3.23). -potential for 0.025% DMAB 
coated nanoparticles declined slightly within the first 7 days from +38.7 mV ± 
1.1 to +35.2mV ± 1.9 and demonstrated a plateau thereafter with surface 
charge of +35.0 mV ± 0.8 at day 28. Prednisolone nanoparticles modified with 
0.01% DMAB showed a slightly lower cationic surface charge profile than from 
0.025% DMAB-coated systems, ranging from +30.4 mV ± 0.7 to +32.7 mV ± 1.1 
(Table 3.15 and Figure 3.24). 
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Table 3.15 Particle size and -potential of 0.025 and 0.01 %w/v DMAB - coated 
prednisolone nanoparticles over 28 days (Mean ± standard error of mean) 
 
 
 0.025% w/v DMAB 0.01% w/v DMAB 
Days Particle size, 
nm±SE 
(PDI±SE) 
-potential 
(+mV) 
±SE 
Particle size, 
nm±SE 
(PDI±SE) 
-potential 
(+mV) 
±SE 
 
0 
 
181.2±11.9 
  
(0.26±0.05) 
 
38.7±1.1 
 
203.3±5.7 
 
(0.18±0.007) 
 
32.3±0.8 
 
7 
 
225.3±18.6 
 
(0.32±0.09) 
  
 
35.2±1.9 
 
203.2±2.4 
 
(0.21±0.01) 
  
 
31.8±1.0 
 
14 
213.5±1.8 
 
(0.32±0.04) 
 
 
36.1±0.8 
209.1±1.9 
 
(0.23±0.01) 
 
 
32.7±1.1 
 
21 
227.8±6.8 
 
(0.30±0.04) 
 
35.1±1.3 
214.9±6.0 
 
(0.17±0.03) 
 
30.6±0.4 
 
28 
206.1±0.3 
 
(0.32±0.06) 
 
35.0±0.8 218.5±6.6 
 
(0.26±0.02) 
 
30.4±0.7 
 
Figure 3.23 Particle size of DMAB - coated prednisolone nanoparticles over 28 
days (Mean ± standard error of mean): 
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In summary, surface modification of prednisolone nanoparticles with 0.01 – 
0.1% w/v DMAB resulted in two different levels of surface charge as illustrated 
in Figure 3.24. Unlike the pattern observed for CTAB – coated nanoparticles 
(Figure 3.20), Table 3.16 and Figure 3.24 show overlapping of -potential 
levels, as surface charge was only slightly different for prednisolone 
nanoparticles when coated with 0.01, 0.025% w/v DMAB on one side, and with 
0.05 and 0.1% w/v DMAB on the other.  
 
 
 
Figure 3.24 - potential of DMAB - coated prednisolone nanoparticles over 28 
days (Mean± standard error of mean) 
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Table 3.16 Summary of  -potential measurements of DMAB - coated 
prednisolone nanoparticles (Mean ± standard error of mean) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.25 Relationship between cationic surfactant concentration and the 
measured particle surface charge of prednisolone nanoparticles, as determined 
on day 14 (Mean ± standard error of mean) 
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DMAB concentration (% w/v) 
Days 
0.01 0.025 0.05 0.1 
0 32.3±0.8 38.7±1.1 69.4±3.5 78.9±1.6 
7 31.8±1.0 35.2±1.9 68.9±2.8 76.4±0.4 
14 32.7±1.1 36.1±0.8 72.5±3.1 75.2±1.2 
21 30.6±0.4 35.1±1.3 68.6±1.1 75.9±2.6 
28 30.4±0.7 35.0±0.8 69.4±0.5 75.1±0.7 
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Figure 3.25 illustrates the proportional relationship between the percent 
concentration of cationic surfactant and the resultant surface charge of coated 
prednisolone nanoparticles. As observed for the coated hydrocortisone 
nanoparticles (Figure 3.13), -potential increases as the surfactant 
concentration increases. For DMAB, a sharp rise in -potential is observed from 
0.025 to 0.5% w/v surfactant indicated by a plateau thereafter. For CTAB, a 
more gradual increase in surface charge is observed as CTAB levels are 
increased. 
For overall comparison between the two steroids, the surface charge against 
CTAB concentration was plotted as a combined plot (Figure 3.26), this takes the 
data from Figures 3.8 and 3.21. The final surface potential is around +50 mV for 
both particles. However, the hydrocortisone surface potential onset to this 
critical maximum value is achieved with an exponential profile, whereas the 
prednisolone exhibits a two-region behaviour one exponential (up to 0.05% 
CTAB) followed by a linear profile thereafter. 
Figure 3.26 Comparison of the effect of CTAB concentration on -potential of 
hydrocortisone and prednisolone nanoparticles, as determined on day 14 
(Mean± standard error of mean) 
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Figure 3.27 Comparison of the effect of DMAB concentration on -potential of 
hydrocortisone and prednisolone nanoparticles, as determined on day 14 
(Mean± standard error of mean) 
 
 
 
 
 
 
Comparing the effect of DMAB concentration on the level of measured -
potential of hydrocortisone and prednisolone particles (data from Figures 3.12 
and 3.25) shows a similar surfactant concentration – surface charge relationship 
for both drug particles (Figure 3.27). The -potential for 0.01% DMAB – surface 
modified particles was recorded to be approximately +30 mV, and continued to 
increase exponentially to reach a maximum surface potential of approximately 
+75 mV for 0.1% w/v levels of DMAB.    
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Figure 3.28 Calibration curve of hydrocortisone in ethanol 
 
 
 
 
Figure 3.29 Calibration curve of prednisolone in ethanol 
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CHAPTER IV 
 
   RESULTS AND DISCUSSION 
  
(DRUG NANOPARTICLES –  
HaCaT CELLS INTERACTION) 
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4.1 Workflow of the current chapter 
This chapter focuses on the results obtained from in vitro studies carried out to 
test the interaction of steroid drug nanoparticles with a keratinocyte cell line 
(HaCaT). This cell - drug nanoparticle interaction was assessed by measuring 
the anti-inflammatory effect of hydrocortisone and prednisolone nanoparticles 
on lipopolysaccharide (LPS) - induced inflammation. Throughout the current 
chapter, the results are presented in the following order:  
(i) the results of HaCaT cell response to the inflammatory stimulation 
with different concentrations of LPS (Section 4.2) 
(ii) the effect of hydrocortisone nanoparticles on NO production of LPS - 
stimulated HaCaT cells (Section 4.3.1) 
(iii) the effect of prednisolone nanoparticles on NO production of LPS - 
stimulated HaCaT cells (Section 4.3.2). 
 
All results presented in this chapter were obtained according to the 
experimental methods described in Chapter II, Sections 2.2.2.2 and 2.2.2.3.  
 
Statistical analysis: 
All results presented in this chapter represent the mean of 3 independent 
experiments ± standard error of mean (Mean ± SE). Statistical analysis of the 
significant differences between different treatments and also when compared to 
control was tested by one - way ANOVA (post hoc: Bonferroni test) using the 
Predictive Analytics Software (PASW Statistics 18, SPSS Inc. UK). 
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4.2 LPS stimulation 
HaCaT cells were treated with of LPS to stimulate the production of NO as 
described in Section 2.2.2.2. This was used as a route to monitor and evaluate 
the inflammatory response of the selected cell line (HaCaT) upon their 
treatment with different concentrations of LPS (0, 10, 50 and 100 g/ml).  The 
results have shown that control HaCaT cells (without LPS treatment) had a 
basal NO production of 9.9 M ± 0.06. Cell preparations treated with LPS 
concentrations of 10, 50 and 100 g/ml induced NO production levels of 10.3 
M ± 0.06, 11.3 M ± 0.36 and 12.8 M ±0.06, respectively (Table 4.1 and 
Figure 4.1). Cell preparations treated with 100 g/ml resulted in significantly 
(p<0.05 – p<0.001) higher NO concentrations when compared to untreated and 
lower LPS concentration-treated cells. Measured NO production levels of cells 
treated with 50 g/ml LPS were significantly (p<0.05) different when compared 
to control cells. 
 
 
Table 4.1 Levels of LPS – induced production of NO in HaCaT cells (Mean ± 
SE of mean) 
 
 
LPS 
concentration 
(g/ml) 
Control 10 50 100 
Mean NO 
concentration 
(M) 
9.9±0.06 10.3±0.06 11.3±0.36 12.8±0.06 
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Figure 4.1 Effect of LPS concentration on NO production levels in HaCaT cells. 
Each column represents the mean of 3 results (Mean ±SE of mean). Where 
*p<0.05, **p<0.01 and ***p<0.001 for significant difference 
 
 
 
 
 
 
4.3 The pharmacological effect of steroid nanoparticles on LPS 
- induced NO production 
4.3.1. EFFECTS OF HYDROCORTISONE NANOPARTICLES 
 
The methods used to evaluate the anti-inflammatory effect of hydrocortisone as 
nanoparticles were carried out as described in Section 2.2.2.3. Briefly, HaCaT 
cell preparations were pre-incubated for 1 hour with drug nanoparticles in serum 
– free culture medium prior to application of LPS (100 g/ml) for 24 hours. A 
new control (drug-untreated cells) culture flask was prepared with every set of 
experiments. 
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achieve final concentrations of either 57 or 75 g/ml hydrocortisone. The 
pharmacological effect of nanoparticles was quantified by measuring the 
amount of released inflammatory mediator nitric oxide (NO) by treated cells 
using a sodium nitrite calibration curve at 570 nm. The anti-inflammatory effect 
of drug nanoparticles was then evaluated by calculating the percentage 
reduction of NO production compared to control (cells treated only with LPS 
without any drug treatment). Hence, and for consistency, the percentage 
reduction of NO of controls was calculated using the same formula, and thus 
percentage NO reduction of control cells was shown to be equal to zero.  
Firstly, all cell preparation treatments were aimed at target drug concentration of 
57 g/ml drug content. Where cells were treated and assayed for a response 
using hydrocortisone solution, uncoated nanoparticle suspensions and CTAB – 
and DMAB – coated hydrocortisone nanoparticles. Percentage reduction in NO 
production was calculated for each treatment as compared to control cells (LPS 
- only treated cells).  
Results showed a reduction in NO production when cells were treated with 
hydrocortisone solution and uncoated nanoparticles prior application of LPS 
(0.56% ± 1.2 and 1.06% ± 0.43 respectively). Even though the NO - reduction 
effects measured with both treatments were small and showed no level of 
significance when compared to control cells, it is important to recognise that the 
effect of drug nanoparticles was almost twice that of the steroid solution (Figure 
4.2).  
Pre-incubation of cell preparations for 1 hour with 0.01, 0.025, 0.05 and 0.1% 
w/v DMAB – coated nanoparticles resulted in inhibition of NO levels by 9.3% ± 
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0.5, 19.1% ± 1.6, 20.2% ± 1.2 and 22.8% ± 1.9, respectively, compared to the 
LPS-only treated cells (Figure 4.2).  
Levels of NO production were significantly (p<0.001) reduced upon pre-
incubation of cell preparations with 0.01 – 0.1% DMAB – coated nanoparticles 
before application of LPS, as compared to control cells.  
 
 
Figure 4.2 Percentage NO reduction effect of hydrocortisone solution, uncoated 
and DMAB – coated nanoparticles (57g/ml). Each column represent mean of 3 
results ±SE of mean.  Where *p<0.05, **p <0.01 and ***p<0.001 for significant 
difference compared to control 
 
 
 
Moreover, the percentage reduction in NO production appeared to be directly 
proportional to the concentration of cationic surfactant. This is probably 
attributed to the level of positive charge of nanoparticles which is a result of the 
surfactant concentration (Figure 3.11.).   
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DMAB-coated nanoparticles (Figure 4.3). Results show the distinguishably 
higher effect of DMAB-coated hydrocortisone nanoparticles over equivalent 
surfactant-only and hydrocortisone-surfactant solutions. The NO-reducing effect 
of 0.1% DMAB-coated particles was significantly (p<0.05 – p<0.001) higher 
when compared to the effect of all solution forms. This finding probably 
indicates a synergic pharmacological effect that is mostly due to the presence of 
hydrocortisone as nanoparticles.   
   
Figure 4.3 Comparisons of the NO-reducing effects of DMAB solution, 
hydrocortisone/DMAB solution and DMAB-coated hydrocortisone particles. 
Each column represent mean of 3 results ±SE of mean.  Where *p<0.05, 
**p<0.01 and ***p<0.001 for significant difference as compared to 0.1% DMAB-
coated particles (Hc-DMAB NP) 
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(100 g/ml), showed a direct correlation of the percentage reduction of NO 
levels to the surfactant concentration (up to 0.05% CTAB), followed by a slight 
drop in NO reduction with 0.1% CTAB – coated nanoparticles. Percentage NO-
reductions were 6.4% ± 1.9, 8.7% ± 1.2, 12.8% ± 1.8 and 10.5% ± 2.3 when 
cells were treated with 0.01, 0.025, 0.05 and 0.1% w/v CTAB-modified particles, 
respectively (Figure 4.4).  Treatment of cells with 0.025, 0.05 and 0.1% CTAB 
resulted in significant (p<0.01 – p<0.001) reductions in NO production as 
compared to control cells. 
 
Figure 4.4 Percentage NO reduction effect of hydrocortisone solution, uncoated 
and CTAB – coated nanoparticles (57g/ml). Each column represent mean of 3 
results ±SE of mean.  Where *p<0.05, **p<0.01 and ***p<0.001 for significant 
difference compared to control 
 
 
 
 
 
 
 
As seen with DMAB, the level of positive charge (as function of the CTAB 
surfactant concentration) of nanoparticles influences the NO-inhibitory effect of 
coated particles (Figures 3.7 and 4.4).   
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Cell preparations were treated with CTAB solution to evaluate its effect on LPS-
induced NO levels in the presence and absence of hydrocortisone (Figure 4.5). 
Unlike the treatment-effect pattern observed for DMAB treatments, incubation of 
cells with CTAB solution (0.01% and 0.025% w/v) resulted in lower NO levels 
than those measured when cells were treated with hydrocortisone-CTAB 
solution or CTAB-coated particles (Figure 4.5). There was however no 
statistically significant difference observed between effects of treatment options. 
The results therefore suggest that at a hydrocortisone concentration of 57g/ml, 
the drug nanoparticles and solutions did not induce a NO-reducing effect 
greater than that of CTAB solutions (except the effects observed with  CTAB-
coated nanoparticles (0.05% and 0.1% w/v) and hydrocortisone-0.1% CTAB 
solution that were higher than those of equivalent CTAB solutions).    
 
Figure 4.5 Comparisons of the NO-reducing effect of CTAB solution 
hydrocortisone/CTAB solution, and CTAB-coated hydrocortisone particles. Each 
column represent mean of 3 results ±SE of mean 
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Figure 4.6 Percentage NO reduction effect of hydrocortisone, uncoated, CTAB- 
and DMAB – coated nanoparticles (57g/ml). Each column represent mean of 3 
results ±SE of mean.  Where *p<0.05, **p<0.01 and ***p<0.001 for significant 
difference compared to uncoated nanoparticles 
 
 
 
These results highlighted the anti-inflammatory effect of coated nanoparticles 
that was found to be higher than that of uncoated nanoparticles and solution 
forms. Figure 4.6 shows that the anti-inflammatory effect of all coated 
hydrocortisone nanoparticles (except 0.01 and 0.025% CTAB-coated particles) 
were significantly (p<0.05 – p<0.001) different when compared statistically to 
equivalent uncoated particles. This is mostly attributed to the cationic surface 
charge of coated particles that enhances particle penetration through cell 
membranes over the anionic charge of uncoated particles. In addition, the NO-
reducing effect of cationic drug particles showed to be correlated to the level of 
positive surface charge. Therefore, it is observed that the higher cationic 
surface charge of DMAB- coated particles resulted in greater NO-inhibitory 
effect when compared to CTAB-coated and uncoated particles (Figure 4.7). The 
NO-reduction effect measured with 0.1% DMAB-coated particles (-potential = 
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+75.6 mV) was significantly (p<0.01 - p<0.001) higher than all other treatments 
(except 0.025 and 0.05% DMAB-coated particles) (Table 4.2).  
 
Table 4.2 Summarizes the analysis of variance (ANOVA) for NO-reducing effect 
of CTAB- and DMAB-coated hydrocortisone particles (57g/ml). # non-
significant difference, *p<0.05, **p<0.01 and ***p<0.001 
 
 
 
Figure 4.7 Relationship between the particle surface charge of hydrocortisone 
nanoparticles (57g/ml) and the percentage NO reduction effect. Each point 
represent mean of 3 results ±SE of mean 
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Figure 4.8 Summarizes the effect of surfactant concentration on the anti-
inflammatory effect (primary vertical axis) and particle surface charge 
(secondary vertical axis) of coated hydrocortisone nanoparticles. Each point 
represent mean of 3 results ±SE of mean 
 
 
 
The anti-inflammatory effects and -potential levels of CTAB-coated particles 
are shown to correlate with the surfactant concentration up to 0.05% w/v level of 
CTAB. Beyond this concentration, higher surface charge did not seem to have a 
positive effect on the anti-inflammatory effect of drug particles with slight drop 
being observed at 0.1% w/v CTAB. Alternatively, DMAB-coated particles 
demonstrated an overall stronger correlation, as the increase in DMAB 
concentration from 0.01 to 0.05% w/v induced a simultaneous enhanced cell 
response in parallel with increasing cationic surface charge. This observation 
was followed by plateau for both parameters at a concentration of 0.1% w/v 
DMAB (Figure 4.8).  
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In separate studies, cell preparations were treated with drug nanoparticles with 
final concentration of 75 g/ml hydrocortisone. Results showed only a small 
difference between the anti-inflammatory effects of hydrocortisone solution and 
uncoated nanoparticles (percent NO reduction of 2.04% ± 1.05 and 2.37% ± 
0.37, respectively). The anti-inflammatory effects of both treatments were 
insignificantly different when compared to control cells (Figure 4.9).  
It was observed that the measured percentage NO-reduction for 75 g/ml 
hydrocortisone nanoparticles (2.37% ± 0.37) was double that observed for the 
57 g/ml nanoparticles (1.06% ± 0.43) despite the drug content being only 
31.6% higher (Figure 4.10). This indicates that the anti-inflammatory effect of 
uncoated nanoparticles was dose – related. However, the difference between 
both treatments was statistically insignificant. 
 
Figure 4.9 Percentage NO reduction effect of hydrocortisone solution and 
different nanoparticles (75g/ml). Each column represent mean of 3 results ±SE 
of mean. Where *p<0.05, **p<0.01 and ***p<0.001 for significant difference 
compared to control  
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Figure 4.10 Comparison of anti-inflammatory effect of hydrocortisone 
nanoparticles with different drug content (Mean± standard error of mean) 
 
 
 
 
 
Pre - incubation of cell preparations with one of the four different loadings of 
DMAB - coated hydrocortisone nanoparticles (0.01 – 0.1% w/v DMAB), prior to 
the application of LPS (100 g/ml) reduced the NO production levels in treated 
cells over LPS- only treated cells.  
Treatment of cell preparations with hydrocortisone particles coated with 0.01 – 
0.1% w/v DMAB resulted in significant (p<0.01 – p<0.001) inhibitory effect on 
NO production in comparison to control cells. In addition, the percentage 
reduction in NO production was directly proportional to surfactant concentration 
up to DMAB 0.05% w/v (22.8% ± 4.1), where a slight decrease was seen 
afterwards with 0.1% DMAB – coated nanoparticles (21.0%± 5.1) (Figure 4.9). 
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Figure 4.11 Percentage NO reduction effect of hydrocortisone solution, 
uncoated and DMAB-coated nanoparticles containing (75g/ml). Each column 
represent mean of 3 results ±SE of mean. Where *p<0.05, **p<0.01 and 
***p<0.001 for significant difference compared to drug solution and uncoated 
nanoparticles.  
 
 
 
 
 
 
 
 
Figure 4.11 show a significant (p<0.001) reduction of NO production levels of 
0.025 - 0.1% w/v DMAB-coated particles as compared to equivalent solution 
and uncoated particles of hydrocortisone at a concentration of 75 g/ml.  
The DMAB concentration - effect relationship is believed to be linked to the -
potential of the particles, where elevated -potential leads to enhanced cellular 
uptake of the modified nanoparticles with cationic surface charge. Labhasetwar 
et al. (1998) reported 4-fold enhanced cellular uptake of DMAB – modified 
polymeric nanoparticles when DMAB concentration was doubled.  
Moreover, this DMAB concentration - effect correlation (observed in Figures 4.2 
and 4.9) is quite similar to the surfactant concentration – surface charge pattern 
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observed in Figure 3.12, where it shows an initial parallel rise (exponential) of 
anti-inflammatory effect up to a DMAB concentration of 0.05% (Figures 4.9 and 
4.12). 
 
Figure 4.12 Relationship between the particle surface charge and percentage 
NO reduction effect of hydrocortisone nanoparticles (75g/ml). Each point 
represent mean of 3 results ±SE of mean. SE of   was small to be visible 
 
 
 
 
 
As a widely accepted perspective, electrostatic attraction occurs between 
surfaces bearing opposite charges. Indeed, this concept has already provided 
the scientific explanation for uptake processes occurring at cellular levels. It has 
been reported that efficient cell transfection (a process describes cell/nuclear 
internalization of DNA) is based on the electrostatic attraction formed between 
the positively - charged DNA/DNA complexes and the negatively - charged 
surface of cell membrane (Sakurai et al., 2000, Torchilin, 2006) and that these 
cationic complexes would bind to the anionic components on cell surface 
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of DNA-complex may be greatly enhanced with increased net positive charge 
(Lungwitz et al., 2005). 
Hence, in regards to the electrostatic attraction of oppositely - charged 
particulates, a similar explanation may be true for an initial attraction of 
positively charged nanoparticles and the negative charge of cell surface, 
followed by cell uptake of these particles.  Hence, cationic nanoparticles would 
probably tend to adhere and accumulate on the anionic outer surface of cell 
membranes, which enables the presence of what resembles a drug-reservoir 
ready for cell penetration. It  is also suggested that this cationic nanoparticles – 
cell surface mechanism may take place by forming ionic interactions with the 
negative cell surface, which eventually enhances nanoparticle penetration and 
retention (Labhasetwar et al., 1998).  Moreover, the use of serum-free culture 
medium possibly may prolong the cell-retention of penetrated nanoparticles, as 
it is suggested that serum-free culture medium inhibits exocytosis of 
nanoparticles,  due to the absence of albumin, a protein present in serum, that 
induces nanoparticles exocytosis (Panyam and Labhasetwar, 2003). Mao et al. 
(2001) reported the effects of serum on the physical properties of chitosan-DNA 
nanoparticles. Mao et al. suggested that the adsorption of serum proteins on the 
surface of nanoparticles resulted in suspension instability, as indicated by high 
increases in particle size due to aggregation as well as decreased -potential 
levels. 
Overall, the current findings clearly show the superiority of positively – charged 
coated nanoparticles over negatively – charged uncoated nanoparticles on 
inhibition of the inflammation effect. Therefore, these findings (summarized in 
Figures 4.7 and 4.12) support evidence in the literature that a positive surface 
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charge enhances cell uptake of nanoparticles over neutral or negatively 
charged particles (Torchilin, 2006, Peetla and Labhasetwar, 2009, Labhasetwar 
et al., 1998). 
The cellular uptake of hydrocortisone nanoparticles by HaCaT cells was imaged 
using TEM as described in Section 2.2.2.4 with the results presented in Figure 
4.14. The micrographs for treated cells indicate the presence of particulate 
accumulations in some cell vesicles (Figure 4.14 B ii, C ii and D ii), with 
diameter close to the particle size determined by DLS before the experiment 
(particle size 428.6, PDI 0.169). These particles were not visible in the 
micrographs of control cells (Figure 4.14 Bi, Ci and Di) taken using the same 
magnification. In addition, the presence of empty vesicles were observed in a 
control cell (Figure 4.14 Ci), but appeared to be full in treated cells (Figure 4.14 
Cii).  This finding probably suggests that these particulates could be drug 
nanoparticles that have entered the cells. However these micrographs could not 
conclusively indicate the cellular uptake of nanoparticles. However, an overall 
difference between the treated and the untreated cells was observed.   
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Figure 4.13 Micrographs of HaCaT cells treated with (A) Hc nanoparticles , (B) 
0.01%CTAB – coated Hc nanoparticles (both with 57g/ml Hc). (i) untreated 
cells (ii) after 1 hour incubation with NP and (iii) after application of LPS for 24 
hours. Scale bar=100m. 
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Figure 4.14 TEM micrographs of HaCaT cells treated with hydrocortisone 
nanoparticles (75g/ml) imaged at acceleration voltage of 2.5, 6, 16.5 and 43kV 
for panels A, B, C and D, respectively. Micrographs A(i) – D(i) represent the 
control cells, and micrographs A(ii) – D(ii) represent the NP-treated cells. 
Arrows show possible intracellular drug nanoparticles. Scale bar = 5, 2, 1m 
and 500nm for panels A, B, C and D, respectively 
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4.3.2 Effect of prednisolone nanoparticles 
 
Prednisolone nanoparticles were investigated for their anti-inflammatory effect 
on LPS – induced NO production on HaCaT cells as described in Section 
2.2.2.3. Cells-coated prednisolone nanoparticle treatments were prepared for 
final concentration of 57g/ml prednisolone.  
Treatment of cells with uncoated prednisolone nanoparticles (1.67 mg/ml) has 
resulted in 9.2% ± 0.5 reduction of LPS – induced NO production.   
Pre-incubation of cells with 0.01 – 0.2% w/v CTAB - coated prednisolone 
nanoparticles resulted in significant (p <0.001) reduction in NO production when 
compared to control. Pre-treatment with 0.01, 0.025, 0.05, 0.1 and 0.2% CTAB 
– coated nanoparticles inhibited NO production levels by 18.9% ± 2.9, 22.4% ± 
0.00, 10.9% ± 0.06, 10.9% ± 0.00 and 11.0% ± 0.06 respectively, with an 
overall percent deviation of 14.8% (Figure 4.15).    
Cell preparations treated with prednisolone nanoparticles modified with 0.025, 
0.05 and 0.1% DMAB (57 g/ml) significantly (p <0.001) inhibited the LPS – 
induced NO production (11.5% ± 0.10, 12.6% ± 0.5 and 11.1% ± 0.5, 
respectively) in comparison to controls, with an overall percent deviation of 
11.7% (Figure 4.15). 
The statistical analysis of variation between all treatments shows that 
prednisolone particles coated with 0.01 and 0.025% w/v CTAB resulted in 
significantly (p<0.05 – p<0.001) lower NO levels than other coated drug 
particles. Reduced NO levels measured with DMAB-coated particles were not 
significantly different to each other (Table 4.3). 
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Figure 4.15 Percentage NO reduction effect of prednisolone nanoparticles. 
Each column represent mean of 3 results ±SE of mean. Where *p<0.05, 
**p<0.01 and ***p<0.001 for significant difference compared to control 
 
 
 
 
 
 
 
 
Table 4.3 Summarizes the analysis of variance (ANOVA) for NO-reducing effect 
of CTAB- and DMAB-coated prednisolone particles (57g/ml). # non-significant 
difference, *p<0.05, **p<0.01 and ***p<0.001 
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Figure (4.15) shows that the highest NO- production suppression effect was 
measured when cell preparations were incubated with 0.025% CTAB - coated 
prednisolone particles. Moreover, this anti-inflammatory effect was significantly 
(p<0.001) different in comparison to all other cell- nanoparticle treatments 
(Table 4.3 and Figure 4.16). 
 
Figure 4.16 Percentage NO reduction effect of prednisolone nanoparticles. 
Each column represent mean of 3 results ±SE of mean. Where *p<0.05, 
**p<0.01 and ***p<0.001 for significant difference compared to 0.025% CTAB-
coated particles 
 
 
 
As with coated hydrocortisone nanoparticles, the effect of surfactant solutions 
on NO levels was compared to the result for coated prednisolone particles. 
Comparisons revealed that CTAB-coated particles resulted in overall greater 
NO reduction effect (15.8%) than the equivalent CTAB solution treatments 
(11.9%). In particular, 0.025% CTAB-coated particles resulted in significantly 
(p<0.01 – p<0.001) lower cellular NO levels than all CTAB solution treatments. 
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The measured NO levels for DMAB solution treatments was however lower than 
NO levels measured with equivalent DMAB-coated particles (Figure 4.17). 
These findings are therefore opposite to the results observed with 
hydrocortisone treatments, showing that particles coated with DMAB resulted in 
greater NO-reducing effect than solutions, whereas CTAB treatments showed 
reverse effects (Figures 4.3 and 4.5). 
 
Figure 4.17 Comparisons of the NO-reducing effect of surfactant solutions and 
surfactant-coated prednisolone particles. Each column represent mean of 3 
results ±SE of mean. Where *p<0.05, **p<0.01 and ***p<0.001 for significant 
difference compared to 0.025% CTAB-coated particles 
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reference, 2009). Thus, one aim of this study was to compare the anti-
inflammatory effect – as percentage NO inhibition - of hydrocortisone and 
prednisolone nanoparticles with equal (57g) drug content. Comparison showed 
a significant (p<0.001) greater reduction in NO production of 0.01 and 0.025% 
CTAB – coated prednisolone nanoparticles when compared with the equivalent 
CTAB – coated hydrocortisone nanoparticles (Figure 4.18). The percentage NO 
– reduction effect increased approximately 3 fold from 6.4% ± 1.9 to 18.9% ± 
2.9 (0.01% CTAB – coated nanoparticles) and from 8.7% ± 1.2 to 22.4% ± 0.0 
(0.025% CTAB – coated nanoparticles).  
 
 
Figure 4.18 Comparison of relative NO-inhibitory effect of CTAB - coated 
hydrocortisone and prednisolone nanoparticles. Each column represent mean 
of 3 results ±SE of mean. Where *p<0.05, **p<0.01 and ***p<0.001 for 
significant difference between equivalent treatments 
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The comparison results presented in Figure 4.18 agree with discussion detailed 
in Section 4.3.1 regarding the role of surface charge (indicated by -potential 
values) on cell penetration, and preferential uptake of positively-charged 
particles over neutral or negative particles. The enhanced anti-inflammatory 
effect of 0.01 and 0.025% CTAB - modified prednisolone nanoparticles over the 
equivalent hydrocortisone nanoparticles is probably explained by the surface 
charge results presented in Figure 3.26, which illustrates that 0.01 and 0.025% 
CTAB - coated prednisolone nanoparticles possess a higher cationic surface 
charge (+7.9mV ± 0.8 and +17.9 mV ± 1.2, respectively) than the 0.01 and 
0.025% CTAB - modified hydrocortisone nanoparticles (+6.3mV ± 0.44 and 
+15.2mV ± 1.4, respectively).  In addition, this may be also attributed to a 
mechanism by which CTAB interacts with particle surface resulting to the 
formation of different levels of surface charge when using same CTAB 
concentration with different drug particles.   
Therefore, the obtained levels of cationic surface charge have probably affected 
the way targeted cells interact with the drug nanoparticles.    
On the other hand, current results revealed that 0.025, 0.05 and 0.1% DMAB - 
coated hydrocortisone nanoparticles had a greater effect over prednisolone 
nanoparticles coated with same surfactant concentrations (Figure 4.19). To 
summarize, the percentage NO - inhibition effect rose from 11.5% ± 0.1 to 
19.1% ± 1.6 (0.025% DMAB – coated nanoparticles), from 12.6% ± 0.5 to 
20.2% ± 1.2 (0.05% DMAB – coated nanoparticles) and from 11.1% ± 0.5 to 
22.8% ± 1.9 (0.1% DMAB – coated nanoparticles) for prednisolone and 
hydrocortisone nanoparticles, respectively. This increase in anti-inflammatory 
effect was significantly higher only with 0.1% w/v DMAB-coated particles. In 
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contrast, the surface charge explanation illustrated above cannot be applied 
here, as - despite the higher anti-inflammatory effect of hydrocortisone 
nanoparticles – the -potential values of the stated surface - modified 
hydrocortisone particles were slightly lower than those of equivalent 
prednisolone particles, excepting the results for 0.025% and 0.1% w/v DMAB 
coated nanoparticles. 
 
 
Figure 4.19 Comparison of relative NO - inhibitory effect of DMAB - coated 
hydrocortisone and prednisolone nanoparticle. Each column represent mean of 
3 results ±SE of mean. Where *p<0.05, **p<0.01 and ***p<0.001 for significant 
difference between equivalent treatments 
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Figure 4.20 Summarizes the measured surface charge of coated 
hydrocortisone and prednisolone nanoparticles, as determined on day 14. Each 
column represent mean of 3 results ±SE of mean 
 
 
 
 
 
 
 
Figure 4.21 Summarizes the measured anti-inflammatory effect of coated 
hydrocortisone and prednisolone nanoparticles. Each column represent mean 
of 3 results ±SE of mean 
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Figures 4.20 and 4.21 summarize the relationship between particle surface 
charge and the resultant reduction in NO levels of coated hydrocortisone and 
prednisolone particles. It was observed that the measured inhibition in NO 
production was correlated to the level of particle cationic surface charge up to 
0.05% w/v concentration of surfactant (up to 0.025% w/v CTAB for prednisolone 
particles). In addition, from the relationship pattern observed in Figure 4.21, 
surfactant-drug particle specificity may be concluded, as CTAB-coated 
prednisolone particles are shown to have better NO-reducing effects than that 
observed with DMAB-coated particles. Alternatively, hydrocortisone particles 
modified with DMAB demonstrated higher NO-reduction effect than equivalent 
CTAB-coated particles. This finding may suggest the formation of sort of "best 
combination' systems (Prednisolone-CTAB and Hydrocortisone-DMAB systems) 
that resulted in enhanced NO-reducing effect than their counterparts 
(Prednisolone-DMAB and Hydrocortisone-CTAB systems, respectively). The 
measured -potential of DMAB-modified prednisolone particles was however 
higher than that measured for particles coated with CTAB, yet demonstrated an 
overall lower NO-reducing effect. This latter finding may also indicate the 
formation of a specific drug-surfactant relationship as stated above.     
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Figure 4.22 Calibration curve of sodium nitrite in serum-free culture medium 
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CHAPTER V 
DISCUSSION  
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5. Discussion 
Overall, this project has focused on the bottom up synthesis of nanomedicines 
and their cellular interactions. Within this project, the notion of nanomedicines 
refers to the use of nanometric scaled active pharmaceutical ingredients (APIs) 
and their use in the diagnosis, prevention and/or treatment of diseases. The 
application of nanomedicines requires underpinning insight into particle 
fabrication of APIs within this size scale. These systems are also termed 
nanopharmaceuticals, which in turn can be fabricated in different forms such as 
nanoemulsions and nanosuspensions (Patravale et al., 2004). Recently, and 
owing to the advantageous physico-chemical properties of nanoparticles, the 
applications of nanomedicines has become extensively explored. The various 
pharmaceutical and medical applications of nanomedicines include the use of 
nanopharmaceuticals in diagnosis (Sahoo and Labhasetwar, 2003, Farokhzad 
and Langer, 2006b) and drug delivery (Rabinow, 2004). It is expected that the 
number of people working on nanomedicinal applications will greatly exceed 
two million within the coming two decades (Bawa, 2009).  
For this expectation to develop, an understanding of how nanoparticles interact 
and penetrate cells is also required, and it was for this reason that nano-drug 
particles were formulated and then examined in relation to cell interactions.   
Specifically, the current project used a method of enhancing the drug delivery of 
two hydrophobic steroid drugs (Hydrocortisone and Prednisolone). Preparation 
and surface modification of the two steroid nanosuspensions in their nanosized 
dimensions was explored.  
As stated in Section 1.1.4.1, one of the many applications of microfluidic 
reactors is to prepare drug nanoparticles (Marre and Jensen, 2010). Therefore, 
P a g e 124 Formation and cell interaction of hydrocortisone and prednisolone nanoparticles  
 
in the first part of this study hydrocortisone and prednisolone nanosuspensions 
were prepared using a bottom-up approach: in which the anti-solvent 
precipitation method using a Y - shaped microchannel reactor was employed 
(Ali et al., 2009b).  The prepared drug nanoparticles were characterized for their 
particle size distribution using DLS, TEM and surface charge ( -potential) using 
Malvern Zetasizer Nano. PXRD and DSC techniques were used to characterize 
the crystalline form for hydrocortisone nanoparticles.  In the present study, both 
uncoated and coated nanoparticles of both drugs were prepared. The term 
"uncoated" was assigned to those drug nanoparticles prepared using only a 
combination of steric (HPMC and PVP) and electrostatic (SDS) stabilizers in 
order to prevent particle aggregation and arrest crystal growth. Whereas, 
"coated" was allocated to drug nanoparticles prepared by coating (tuning the 
surface) of the previously-made uncoated nanoparticles with one of two 
selected cationic surfactants: CTAB or DMAB. However, the uncoated 
nanoparticles used to prepare the surfactant-coated nanoparticles were 
prepared with only the two steric stabilizers (HPMC and PVP) without SDS.   
Stability studies were carried out for coated hydrocortisone and prednisolone 
nanoparticles by monitoring their particle size, size distribution and -potential 
over 28 days. 
Results of preparation of hydrocortisone nanoparticles were presented in 
Section 3.2.  Prepared uncoated hydrocortisone nanoparticles exhibited a fairly 
good particle size profile of 466.0 nm ± 16.5 (day 0) and 446.0 nm ± 6.3 (on day 
21), with narrow-ranged size distribution profile as indicated by recorded low 
polydispersity indices (between 0.11 and 0.17) throughout 21 days (Table 3.1 
and Figure 3.1). This probably attributed to the optimum particle stabilization 
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gained upon the use of the recommended combination of both steric and 
electrostatic surfactants (Kesisoglou et al., 2007).  
-potential values indicated negative surface charge of the bare nanoparticles 
which ranged between -1.46mV ± 0.04 and -2.06 mV ± 0.4 over 21 days.  
Though -potential of ±20 mV is a rough guide line for stable nanosuspensions 
of combined steric and electrostatic stabilization (Patravale et al., 2004, Jacobs 
et al., 2000), the measured -potential of hydrocortisone nanoparticles was 
lower than that range and still stable up to 21 days. This stability was indicated 
by the particle size and -potential values that have changed only within narrow 
range throughout 21 days.  
TEM images of uncoated hydrocortisone nanoparticles supported the average 
particle size measured by DLS (Figure 3.2).  
Coated nanoparticles were prepared by particle surface modification with the 
aid of one of two cationic surfactants: CTAB and DMAB. The measured levels 
of surface positive charge (as -potential) of formed coated nanoparticles 
indicated the adsorption of cationic surfactants on particles surface, as they 
reversed the previously-anionic surface charge (of uncoated particles) into 
cationic -potential. 
Hydrocortisone nanoparticles coated with 0.01, 0.025, 0.05, 0.1 and 0.2% w/v 
CTAB were measured for their particle size and surface charge for 28 days 
(Section 3.2.2.1). The overall particle size of CTAB-coated nanoparticles 
remained within the range between 147.2 nm ± 12.2 and 205.7 nm ± 11.8 
throughout 28 days (Tables 3.2, 3.3 and 3.4, Figures 3.5 and 3.6). 
The size distribution range correlated with surfactant concentration.  As 
measured PDI values were higher with the 0.2, 0.1 and 0.05% w/v CTAB-
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coated nanoparticles (up to 0.37 ± 0.06) than with 0.025 and 0.01 % w/v CTAB 
(between 0.18± 0.02 and 0.27± 0.02). This may be due to the concentration of 
CTAB solution affecting the way surfactant molecules are deposited on particles 
surfaces. So the more concentrated surfactant solutions may deposit more 
irregularly over particle surface than the diluted solutions, resulting in wider 
range of particle size distribution due to heterogeneity of particle sizes. Wang 
and Gu (2004) observed that CTAB concentration strongly affected the size and 
size distribution of coated silver nanoparticles and reported that excessive 
CTAB concentration caused particles to coalesce to form large lumps. It is 
assumed that this concept also applies to DMAB –coated particles; as higher 
surfactants concentrations resulted in higher average particle size and broader 
size distribution. 
Measured -potential of CTAB – coated nanoparticles was directly proportional 
to the surfactant concentration (Table 3.5 and Figure 3.7). 
-potential values were measured on day 0 were +6.0 mV ± 0.57, +14.3 mV ± 
1.1, +36.1 mV ± 2.1, +45.9 mV ±2.1 and +52.0 mV ± 1.7 for 0.01, 0.025, 0.05, 
0.1 and 0.2% w/v CTAB concentrations, respectively. 
This is mainly due to the concentration of cationic surfactant solution controlling 
the level of resulting positive (cationic) surface charge. However, this surfactant 
concentration – surface charge relationship shows higher correlation up to 0.05 
% CTAB, followed by a plateau in the effect. This may be due to the "saturable" 
nature of the particle surfaces, where no significant increase in -potential is 
detected beyond that measured using 0.1% w/v CTAB.   
Hydrocortisone nanoparticles modified with 0.01, 0.025, 0.05 and 0.1% w/v 
DMAB resulted in particle size measurements ranging between 148.8 nm ± 13.9 
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and 423.8 nm ± 45.4 over 28 days (Section 3.2.2.2.). As with CTAB – coated 
nanoparticles, PDI values of DMAB - coated nanoparticles were related to 
surfactant concentration and ranged from 0.22 ± 0.02 to 0.66 ± 0.07 for 0.01 - 
0.1% w/v DMAB, respectively (Tables 3.6 and 3.7, Figures 3.9 and 3.10) . 
The -potential of DMAB- coated nanoparticles was directly proportional to 
surfactant concentration. Measured  -potential on day 0 for 0.01, 0.025, 0.05 
and 0.1 % w/v DMAB were +30.2 mV ± 1.6, +44.5 mV ± 3.6, +66.1 mV ± 1.2 
and +75.9 mV ± 2.0, respectively (Figure 3.11). 
The relationship between the concentration of cationic surfactant used and the 
particle -potential  of CTAB – and DMAB -  coated hydrocortisone 
nanoparticles  presented in Figures 3.8 and 3.12, show the direct correlation 
between both parameters . Particle surfaces seemed to be more sensitive to 
DMAB, as -potential values were nearly double those of CTAB – coated 
nanoparticles when comparing equal concentrations of both surfactants (Figure 
3.13). This finding is supported by Peetla and Labhasetwar (2009) who also 
reported higher -potential measurements of DMAB- (+57.74 mV) over CTAB- 
coated polystyrene nanoparticles (+39.25 mV) at equal (0.2% w/v) surfactant 
concentrations. In spite of the different -potential values, which are probably 
related to the properties of the two different core nanoparticles, both show the 
same pattern of higher surface charge for DMAB- over CTAB- coated 
nanoparticles. In addition, the different chemical structure of both cationic 
surfactants affects the way they coat or mask the nanoparticle. Peetla and 
Labhasetwar (2009) suggest that the dichained surfactants (e.g. DMAB) anchor 
differently to solid interfaces than do the single - chained surfactants (e.g. 
CTAB). 
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TEM analysis of DMAB-coated nanoparticles (Figure 3.14 and 3.15) provides 
evidence for the deposition of the cationic surfactant DMAB on particle 
surfaces. The micrographs show the coated nanoparticles with an inner particle 
appearing as a pale core surrounded by a slightly darker outer layer. This outer 
layer probably represents the surfactant coating. 
It was observed with uncoated and surfactant-coated hydrocortisone 
nanoparticles that particle size and -potential measurements were fairly stable 
over 21 and 28 days, respectively.  This is probably attributed to the stability of 
the precipitated nanoparticles owing to the use of the combination of both steric 
(HPMC and PVP) and electrostatic stabilizers (SDS) that is generally 
recommended for optimum stabilization of nanosuspensions (Kesisoglou et al., 
2007). However, the use of only steric stabilizers in the preparation of coated 
nanoparticles has also resulted in stable nanosuspensions over 4 weeks, which 
may be due to an additional stabilizing effect of the cationic surfactant itself.    
On the other hand, using the same stabilizer combination (0.2% HPMC, 0.2% 
PVP and 0.05% w/v SDS) did not seem to work effectively with uncoated 
prednisolone nanoparticles (Section 3.3.1), where they showed a fairly good 
size profile on the day of preparation (PDI 0.16 ± 0.01), but particle growth 
occurred on the following day. Therefore, preparing stable uncoated 
prednisolone nanosuspensions would require more extensive experiments to 
find the perfect stabilizer combination for optimum stability of these colloidal 
systems.  TEM micrographs of prednisolone nanoparticles showed particles 
with irregular outer surfaces (Figures 3.17).  
Prednisolone nanoparticles coated with 0.01% – 0.2% w/v CTAB (Section 
3.3.2.1.) resulted in particle size measurements between 154.9 nm ±13.7 and 
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271.4 nm ±6.9. PDI values ranged between 0.16 ± 0.01 and 0.3 ± 0.04 which in 
turn indicates a relatively narrow particle size distribution of nanosuspensions. 
No marked particle growth was detected for these coated nanoparticles.  
-potential of CTAB – prednisolone coated nanoparticles as measured on day 0 
was +7.1 mV ± 0.3, +16.4 mV ± 2.2, +30.7 mV ± 0.9, +40.9 mV ± 0.3 and +59.6 
mV± 3.3 for 0.01%, 0.025%, 0.05%, 0.1% and 0.2% w/v CTAB, respectively. 
Hence, and as seen with coated hydrocortisone nanoparticles, surface charge 
was directly proportional to percent surfactant concentration used (Figure 3.20).    
DMAB-coated prednisolone nanoparticles were monitored for their particle size 
and -potential over 28 days (Section 3.3.2.2). As seen with hydrocortisone 
nanoparticles, average particle size and PDI values were greater than the 
corresponding CTAB-coated nanoparticles. This may be due to the particle- 
surfactant interaction, which controls the pattern by which the surfactant 
surrounds the particle surface and ultimately affects the particle size.  
Particle size of DMAB-coated prednisolone nanoparticles measured in the 
range 181.2 nm ± 11.9 and 389.6 nm ± 54.9. Higher PDI values were recorded 
with 0.1% w/v DMAB (PDI 0.68 ± 0.08) and decreased correspondingly as the 
DMAB concentration decreased, until PDI of 0.17 ± 0.03 were observed for 
0.01% w/v DMAB- coated particles.   
The surface charge of 0.01%, 0.025%, 0.05% and 0.1% w/v DMAB-coated 
prednisolone nanoparticles was +32.3mV ± 0.8, +38.7 mV ± 1.1, +69.4 mV ± 
3.5 and +78.9 mV ± 1.6, respectively on day 0 (Figure 3.24) . However, 
measured -potentials were less different for the range of DMAB 
concentrations, unlike the observations made for CTAB – coated particles 
(Figure 3.20).  
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Despite the stability issue encountered with uncoated prednisolone 
nanoparticles, it is important to recognise that these nanoparticles were 
stabilized over 4 weeks when they were coated with CTAB (Section 3.3.2.1) 
and DMAB (Section 3.3.2.2). This observation may indicate an additional 
particle stabilizing effect gained by the adsorbed cationic surfactant, and which 
is verified by the relatively stable particle size and -potential profiles throughout 
the whole period.  
The relationship between the surfactant concentration and resultant  -potential 
of coated prednisolone nanoparticles was summarized (Figure 3.25) and shows 
that adsorption of DMAB on particle surface resulted in nearly double -potential 
values than those measured using equal concentrations of CTAB surfactant  .   
The effect of CTAB concentration on the surface charge of hydrocortisone and 
prednisolone nanoparticles was compared (Figure 3.26). The comparison plot 
showed exponential relationship for hydrocortisone nanoparticles, whereas 
prednisolone exhibited an initial exponential trendline up to (0.05% w/v CTAB) 
followed by linear relationship before surface charge of both steroids reach an 
approximately equal maximum value of +50 mV. 
Similarly, the relationship between DMAB concentration and the resulted 
cationic surface charge of hydrocortisone and prednisolone particles was 
evaluated. Both hydrocortisone and prednisolone nanoparticles exhibited a very 
similar trend, where their -potential increased exponentially up to 0.05% w/v 
surfactant concentration, followed by a plateau (Figure 3.27).  
In the second part of this study, the anti-inflammatory effect of hydrocortisone 
and prednisolone nanoparticles was studied by measuring the percent reduction 
of NO (an inflammatory mediator) induced by steroid nanoparticles. HaCaT 
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cells (a mammalian keratinocyte cell line) were examined for their response to 
LPS treatment as an inflammatory promoter (Section 4.2). This response was 
quantified by measuring the released NO (an inflammatory mediator) as a 
response to the LPS - induced inflammation (Yu et al., 2009). Cell preparations 
treated with LPS (0, 10, 50 and 100 g/ml) induced NO production levels of (9.9 
M ± 0.06, 10.3 M ± 0.06, 11.3 M ± 0.36 and 12.8 M ± 0.06, respectively) 
(Table 4.1 and Figure 4.1). NO production levels increased with increments in 
LPS concentration, which indicates the response of HaCaT cells to the LPS-
induced inflammatory stress. Treatment of cells with 50 g/ml LPS promoted a 
significant (p<0.05) increase in NO production levels compared to untreated 
control cells. Treatment of cells with 100 g/ml resulted in significantly (p<0.05 – 
p<0.001) higher NO-production levels as compared to 0, 10 and 50 g/ml LPS 
treatments. 
In separate experiments, cells were tested for their cellular uptake of steroid 
nanoparticles by measuring the resultant reduction in NO levels compared to 
control. 
Pre-incubation of cell preparations with hydrocortisone solution, uncoated and 
coated nanoparticles (all with 57 g/ml drug content) resulted in overall 
reduction of NO levels in the following order:  
 
DMAB- > CTAB-coated nanoparticles >> uncoated nanoparticles >solution 
The overall percent NO reduction effects were in the order of 17.9% ± 1.3, 9.6% 
± 1.8, 1.06% ± 0.43 and 0.56% ± 1.2, respectively (Section 4.3.1). Treatment 
with hydrocortisone solution and uncoated particles did not significantly affect 
the cellular production levels of NO. 
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Whereas, significant (p<0.01) reduction in NO production was measured when 
cells were treated with 0.025% CTAB-coated particles and even more 
significant (p<0.001) reduction in NO levels was measured for cells treated with 
0.05, 0.1% CTAB- and 0.01, 0.025, 0.05 and 0.1 % w/v DMAB-coated 
hydrocortisone particles (Figures 4.2 and 4.4). 
The possible effects of surfactant solutions (with or without drug) on NO levels 
were evaluated. Results showed the higher NO-inhibitory effect of DMAB-
coated particles over equivalent solutions. In particular, drug particles coated 
with 0.1% w/v DMAB inhibited NO production significantly (p<0.05 – p<0.001) 
when compared to all solution treatments (Figure 4.3). Alternatively, treatment 
of cells with CTAB-only and CTAB-hydrocortisone solutions resulted in lower 
NO levels than with equivalent coated drug particles, except 0.05% CTAB-
coated drug particles that resulted in lower NO levels than most solution 
treatments (Figure 4.5). There was however no significant difference between 
effects of CTAB treatment options.  These findings therefore suggest that at a 
hydrocortisone concentration of 57 g/ml, the synergistic anti-inflammatory 
effect of surfactant-drug particles could inhibit NO-production than the 
equivalent with/without-drug solution treatments, with DMAB but not for CTAB 
(except 0.05% w/v CTAB-modified particles). The NO-reducing effects of CTAB 
and DMAB solutions may probably indicate an interference of these surfactants 
with LPS effect. Owing to the application of surfactant-containing systems to the 
cells prior LPS, any remained traces of surfactant may form a film-like barrier on 
cells surface, preventing LPS from interacting with cells, leading eventually to 
lower NO release. Moreover, the negative charge of LPS may also enhance its 
adherence to any trace of remained cationic surfactant/particle systems on cells 
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surface. For future studies, this artefact could be minimized by either rinsing the 
cells more frequently, to verify the complete removal of any particle/surfactant, 
or by application of LPS to the cells before incubation with particle/surfactant 
systems. 
Figure 4.6 presents the significantly (p<0.05 – p<0.001) enhanced anti-
inflammatory effect of cationic surfactant – coated nanoparticles over uncoated 
drug nanoparticles, which is most likely due to the nature of surface charge 
(cationic versus anionic charge). It is reported that positively - charged particles 
exhibit greater cell penetration profiles over neutral or negatively-charged 
particles (Torchilin, 2006, Peetla and Labhasetwar, 2009, Labhasetwar et al., 
1998). 
Apart from the different cell interaction behaviours of anionic and cationic 
particles, the measured difference in cell response between cationic 
nanoparticles (CTAB and DMAB), indicates the effect of the degree of this 
cationic surface charge on particle-cell interaction. As higher surfactant 
concentrations (and eventually -potential levels) have shown a correspondent 
significantly higher NO-inhibition cell response (Figures 4.7 and 4.8). The 
results of one-way-ANOVA for coated hydrocortisone particles (57 g/ml) were 
summarized in Table 4.2, showing an overall significantly (p<0.05 – p<0.001) 
higher reductions in NO levels of DMAB- over CTAB-coated particles. These 
findings are in agreement with those reported by Peetla and Labhasetwar 
(2009), where nanoparticles coated with DMAB cationic surfactant induced an 
enhanced cell penetration and uptake over CTAB-coated nanoparticles in an 
endothelial cell model membrane. In addition to the -potential factor, Peetla 
and Labhasetwar (2009) reported that the degree of hydrophobicity may also 
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have a role, as DMAB is more hydrophobic than CTAB due to its dichained 
nature, in addition to the detergent effect of DMAB that may increase the 
permeability of cell membrane. Although cell transfection is a slightly different 
process to that of cellular uptake of nanoparticles, it is suggested that -
potential is a determinant factor for the degree of affinity of a gene-delivery 
complex for charged cell surfaces. Duguid et al. (1998 ) reported that -potential 
-in spite of the presence of other affecting factors- is regarded as the 
measurable indicator that combines all the factors affecting DNA transfection 
efficiency.  Therefore, -potential plays an important role in the various cell – 
internalization mechanisms for extracellular particles. 
Cell preparations were tested with hydrocortisone solution, uncoated and 
DMAB-coated nanoparticle treatments (containing 75 g/ml hydrocortisone). 
The overall treatment - response trend was similar to that observed upon 
treatment with 57 g/ml hydrocortisone. Where pre-treatment of cells with 0.01, 
0.025 0.05 and 0.1% w/v DMAB- coated nanoparticles resulted in significant 
(p<0.01 – p<0.001) reduction in NO production levels, when compared to 
untreated cell preparations (Figure 4.9). The findings of these experiments 
indicate that an increasing particles positive surface charge has significantly 
(p<0.001) enhanced the anti-inflammatory effect of 0.025 – 0.1% w/v DMAB – 
coated hydrocortisone nanoparticles when compared to equivalent uncoated 
particles (Figures 4.11 and 4.12).  
Cells were imaged using transmission electron microscopy (TEM) to examine 
the possible uptake of drug particles by HaCaT cells. Overall, the presence of 
particulates (which lie in the size range of applied drug particles) was observed 
in the images for treated cells but not in those of control cells, which probably 
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indicate some penetration of particles into the cells (Figure 4.14). The obtained 
micrographs did not however conclusively show cellular uptake of 
nanoparticles. The particles were not adequately electron dense to be clearly 
visible, particularly in the rich-in-organelles cytoplasm. Moreover the 
concentration of applied drug nanosuspension (75 g/ml) and the incubation 
period (1 hour) were probably not sufficient to show notable cell uptake. This 
suggests that a different imaging technique may be employed with HaCaT cells, 
as fluorescence microscopy. Naha et al. (2010) reported the cell uptake of 
fluorescently labelled nanoparticles by HaCaT cells (with main particle 
localization in lysosomes), as imaged using confocal laser scanning microscopy 
following 24 hours incubation with nanoparticles at concentrations up to 100 
g/ml.  
In separate experimental studies, the NO production - inhibitory effects of 
prednisolone nanoparticles were investigated (Figure 4.15). Reduction in NO 
levels (from 11.0 ± 0.06 to 22.4% ± 0.00) resulting from treatment of cells with 
0.01 – 0.2% w/v CTAB-modified prednisolone nanoparticles, were significantly 
(p<0.001) different as compared to control cells. 
Pre-incubation of cell preparations with 0.025, 0.05 and 0.1% DMAB-coated 
nanoparticles resulted in significantly (p <0.001) reduced release of NO (by 11.5 
± 0.12, 12.6 ± 0.5 and 11.2% ± 0.5, respectively) in comparison to control cells.   
The one-way ANOVA between CTAB- and DMAB-modified prednisolone 
particles indicated a greater (p<0.05 – p<0.001) NO-lowering effect for 
prednisolone particles coated with 0.01- and 0.025% w/v CTAB over the other 
coated particles (Table 4.3 and Figure 4.16) 
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Based on the data presented in Figures 4.3 and 4.5, the effects of surfactant 
solutions were compared to those of coated prednisolone particles (Figure 
4.17). This evaluation revealed that an overall higher percentage NO-lowering 
effect was observed with CTAB coated particles (15.8%) over CTAB solution 
(11.9%). 
The effects of 0.025% w/v CTAB-coated particles were significantly (p<0.001) 
higher compared to all CTAB solution concentrations. In contrast, DMAB-coated 
particles did not induce higher NO-inhibitory effects than DMAB solutions. It can 
be concluded from the findings observed in Figures 4.3, 4.5 and 4.17, that 
DMAB-coated hydrocortisone and CTAB-coated prednisolone particles were the 
most effective combinations. The anti-inflammatory effects of these systems 
over their counterparts were compared and evaluated (Figures 4.18 and 4.19). 
Prednisolone particles modified with 0.01 and 0.025% w/v CTAB showed a 
significantly (p< 0.001) improved NO reduction effect over equivalent CTAB-
coated hydrocortisone particles (Figure 4.18). The percentage NO – reduction 
effect increased nearly 3 fold from 6.4% ± 1.9 to 18.9% ± 2.9 (0.01% CTAB – 
coated nanoparticles) and from 8.9% ± 1.2 to 22.4% ± 0.00 (0.025% CTAB – 
coated nanoparticles) moving from prednisolone to hydrocortisone particles, 
respectively.  This is probably due to the higher -potential levels of these two 
coated prednisolone particles when compared to equivalent hydrocortisone 
particles (Figure 3.26).  
In the case of 0.025, 0.05 and 0.1% w/v DMAB-modified nanoparticles, 
hydrocortisone exhibited greater inhibition of NO production than equivalent 
prednisolone particles (Figure 4.19). However, the -potential- response 
relationship was inversely proportional in this case (except for 0.025% - DMAB 
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coated particles). The measured -potential values of 0.05 and 0.1% w/v DMAB 
- modified hydrocortisone nanoparticles were slightly lower than those of 
equivalent prednisolone nanoparticles. This effect was significantly (p<0.01) 
higher only for the 0.1% DMAB-coated particles. 
These findings may indicate that a kind of surfactant-drug specificity may exist 
leading to optimum effects. Another probable explanation is the positive effect 
of cationic surface charge on the anti-inflammatory effect of drug particles. 
Figures 4.20 and 4.21 summarize the measured -potentials and the quantified 
reduction in NO level for hydrocortisone and prednisolone drug nanoparticles.   
However, the surface charge theory may explain the observed anti-
inflammatory effect up to surfactant concentration of 0.025-0.05% w/v, above 
which any increase in surface charge lead to plateau effect (which probably 
suggest surface charge saturation). Moreover, the presence of a specific 
surfactant-drug relationship may also justify the higher NO-reduction effect 
observed with 0.01 and 0.025% w/v CTAB- over equivalent DMAB-coated 
prednisolone particles, though particles have lower cationic surface charge.  
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Conclusions 
 
The research area of nanomedicines is rapidly developing worldwide. This 
development is driven primarily by the need to employ the concept of nanoscale 
drugs to overcome issues and hurdles faced in pharmaceutical technology and 
industry.  Of particular importance is the use of nanotechnology to enhance the 
bioavailability of hydrophobic drugs. In the current study, nanosuspensions of 
hydrocortisone and prednisolone; both, poorly-water soluble steroid drugs, were 
prepared using the antisolvent precipitation method using Y – shaped 
microchannel reactors. The microchannel reactor afforded a robust and direct 
route for precipitation of stable drug nanoparticles which were within a fairly 
narrow size distribution. The subsequent surface modification of hydrocortisone 
and prednisolone drug nanoparticles was achieved by adsorption of different 
concentrations of CTAB and DMAB cationic surfactants, respectively. This 
resulted in stable nanoparticle suspensions with different levels of cationic 
surface charge that was found to be tuneable as reflected by -potential 
measurements.  
With regard to the nano drug – cell response activity, this was explored for both 
the uncoated and coated hydrocortisone nanoparticles and coated prednisolone 
particles. This was evaluated by tracking particle cellular uptake by HaCaT cells 
through assessing the overall NO response of the cells to the steroids. 
Interestingly, results demonstrated the enhanced anti-inflammatory effects of 
cationic nanoparticles over uncoated nanoparticles, and both were higher than 
equivalent solution forms (hydrocortisone particles). Furthermore, the measured 
pharmacological effects of cationic nanoparticles were strongly correlated to the 
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level of their cationic surface charge (hydrocortisone and prednisolone 
particles). This finding indicates how prudent manipulation of particle surface 
with cationic surfactants may enable a means of controlling the cell - 
nanoparticle interaction, and could promise improved pharmacological effects of 
hydrophobic therapeutic agents. TEM imaging however, did not conclusively 
indicate the particle uptake by cells. Recommendation for future work should be 
focussed on determining the dissolution characteristic studies to assess the 
impact of surfactant adsorption and further exploration of the mechanism of 
improved efficacy for steroid nanoparticles should also be conducted in the 
cellular environment, carrying out longer stability studies.  Also, undertaking 
alternative protocol(s) for the in vitro studies, in order to minimize any possible 
interference with LPS interaction with cells, is recommended.  In addition, it 
would be beneficial to study and evaluate the cellular uptake of steroid 
nanoparticles by different cell lines and primary cells and using an appropriate 
imaging technique, as confocal laser microscopy. 
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